AU2001264563A1 - Albumin fusion proteins - Google Patents

Albumin fusion proteins

Info

Publication number: AU2001264563A1
Authority: AU; Australia
Prior art keywords: fusion proteins; albumin fusion; albumin; proteins; fusion
Prior art date: 2000-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001264563A

Inventor

William A. Haseltine

Craig A Rosen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Human Genome Sciences Inc

Original Assignee

Human Genome Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-12

Filing date

2001-04-12

Publication date

2001-10-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001264563(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-12 Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc

2001-10-30 Publication of AU2001264563A1 publication Critical patent/AU2001264563A1/en

Status Abandoned legal-status Critical Current

Links

102000009027 Albumins Human genes 0.000 title 1
108010088751 Albumins Proteins 0.000 title 1
102000037865 fusion proteins Human genes 0.000 title 1
108020001507 fusion proteins Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Virology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Dermatology (AREA)
Communicable Diseases (AREA)
Neurosurgery (AREA)
General Engineering & Computer Science (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)

AU2001264563A 2000-04-12 2001-04-12 Albumin fusion proteins Abandoned AU2001264563A1 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US22935800P	2000-04-12	2000-04-12
US60229358		2000-04-12
US19938400P	2000-04-25	2000-04-25
US60199384		2000-04-25
US25693100P	2000-12-21	2000-12-21
US60256931		2000-12-21
PCT/US2001/011850 WO2001079442A2 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Publications (1)

Publication Number	Publication Date
AU2001264563A1 true AU2001264563A1 (en)	2001-10-30

Family

ID=27394014

Family Applications (7)

Application Number	Title	Priority Date	Filing Date
AU2001259066A Abandoned AU2001259066A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001264563A Abandoned AU2001264563A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001274809A Abandoned AU2001274809A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001266557A Abandoned AU2001266557A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001259063A Abandoned AU2001259063A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001262942A Abandoned AU2001262942A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001261024A Abandoned AU2001261024A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AU2001259066A Abandoned AU2001259066A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Family Applications After (5)

Application Number	Title	Priority Date	Filing Date
AU2001274809A Abandoned AU2001274809A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001266557A Abandoned AU2001266557A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001259063A Abandoned AU2001259063A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001262942A Abandoned AU2001262942A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins
AU2001261024A Abandoned AU2001261024A1 (en)	2000-04-12	2001-04-12	Albumin fusion proteins

Country Status (10)

Country	Link
US (23)	US6994857B2 (en)
EP (21)	EP2298355A3 (en)
JP (9)	JP2003530852A (en)
AU (7)	AU2001259066A1 (en)
BE (1)	BE2016C059I2 (en)
CA (8)	CA2405563A1 (en)
DK (2)	DK2236152T3 (en)
ES (2)	ES2484966T3 (en)
FR (1)	FR16C0043I2 (en)
WO (7)	WO2001079271A1 (en)

Families Citing this family (654)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (en) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6057287A (en)	1994-01-11	2000-05-02	Dyax Corp.	Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en)	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
WO2002028877A1 (en) *	2000-09-29	2002-04-11	Human Genome Sciences, Inc.	24 human secreted proteins
WO2001034769A2 (en) *	1999-11-05	2001-05-17	Human Genome Sciences, Inc.	24 human secreted proteins
WO2002016389A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	23 human secreted proteins
WO2002024719A1 (en) *	2000-09-20	2002-03-28	Human Genome Sciences, Inc.	21 human secreted proteins
US20020137890A1 (en)	1997-03-31	2002-09-26	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (en) *	1997-07-09	2000-03-08	Hoechst Marion Roussel Deutschland GmbH	Human and murine semaphorin L
US20030170795A1 (en) *	1997-09-18	2003-09-11	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999066054A2 (en) *	1998-06-15	1999-12-23	Genzyme Transgenics Corp.	Erythropoietin analog-human serum albumin fusion protein
US20050181482A1 (en) *	2004-02-12	2005-08-18	Meade Harry M.	Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20040199099A1 (en) *	1998-07-10	2004-10-07	Matson James R	Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
DE69926009D1 (en)	1998-10-13	2005-08-04	Univ Georgia Res Found	STABILIZED BIOACTIVE PEPTIDES AND METHODS FOR IDENTIFICATION, SYNTHESIS AND USE
US20030190740A1 (en)	1998-10-13	2003-10-09	The University Of Georgia Research Foundation, Inc	Stabilized bioactive peptides and methods of identification, synthesis, and use
ES2260009T3 (en) *	1999-05-05	2006-11-01	Phylogica Limited	INSULATION OF BIOLOGICAL MODULATORS FROM BANKS OF BIODIVERSE GENETIC FRAGMENTS.
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
EP1224285A4 (en) *	1999-10-29	2004-12-08	Human Genome Sciences Inc	27 human secreted proteins
JP2003520030A (en) *	1999-11-05	2003-07-02	ヒューマンジノームサイエンシーズ，インコーポレイテッド	28 human secreted proteins
AU1472701A (en) *	1999-11-12	2001-06-06	Human Genome Sciences, Inc.	28 human secreted proteins
WO2001039722A2 (en)	1999-11-30	2001-06-07	Mayo Foundation For Medical Education And Research	B7-h1, a novel immunoregulatory molecule
DE60041564D1 (en)	1999-12-24	2009-03-26	Genentech Inc	Methods and compositions for extending the disposal half-life of bioactive compounds
US7534417B2 (en)	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) *	2000-03-24	2007-11-06	Immunocept, L.L.C.	Hemofiltration methods for treatment of diseases in a mammal
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2298355A3 (en) *	2000-04-12	2011-06-29	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7030219B2 (en) *	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
WO2001085936A1 (en) *	2000-05-12	2001-11-15	Merck Patent Gmbh	F-box containing protein
US6787040B2 (en) *	2000-05-16	2004-09-07	Immunocept, L.L.C.	Method and system for colloid exchange therapy
AU2001274923A1 (en) *	2000-05-23	2001-12-03	Lexicon Genetics Incorporated	Novel human thrombospondin-like proteins and polynucleotides encoding the same
DE60132699T2 (en)	2000-06-06	2009-01-29	Bristol-Myers Squibb Co.	NUCLEIC ACIDS AND POLYPEPTIDES RELATING TO B7 AND THEIR USES FOR IMMUNOMODULATION
WO2001094391A2 (en) *	2000-06-08	2001-12-13	Incyte Genomics, Inc.	Intracellular signaling proteins
CA2414228A1 (en) *	2000-06-21	2001-12-27	Amgen, Inc.	Secreted epithelial colon stromal-1 polypeptides, nucleic acids encoding the same and uses thereof
EP1311669A4 (en) *	2000-08-18	2004-07-14	Human Genome Sciences Inc	11 human secreted proteins
CA2418676A1 (en) *	2000-08-18	2002-02-28	Human Genome Sciences, Inc.	21 human secreted proteins
EP1313761A4 (en) *	2000-08-28	2005-01-26	Human Genome Sciences Inc	18 human secreted proteins
AU2001296235A1 (en) *	2000-10-12	2002-04-22	Hyseq, Inc.	Novel nucleic acids and polypeptides
US6949371B2 (en)	2000-10-20	2005-09-27	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6531297B2 (en) *	2000-10-20	2003-03-11	Applera Corporation	Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (en) *	2000-10-30	2002-05-03	Inst Nat Sante Rech Med	RENIN AND / OR PRORENIN RECEPTOR PROTEIN, NUCLEIC ACID ENCODING THE RECEPTOR AND THEIR APPLICATIONS
WO2002046228A2 (en) *	2000-12-05	2002-06-13	Wisconsin Alumni Research Foundation	Receptor for b. anthracis toxin
HU230603B1 (en)	2000-12-07	2017-03-28	Eli Lilly And Company	Glp-1 fusion proteins
US20030148920A1 (en) *	2000-12-27	2003-08-07	Steven Rosen	Sulfatases and methods of use thereof
EP1354950A4 (en) *	2000-12-28	2005-01-12	Asahi Kasei Pharma Corp	Nf-kb activating gene
CA2433469A1 (en) *	2001-02-23	2002-09-06	Human Genome Sciences, Inc.	83 human secreted proteins
EP1365801A4 (en) *	2001-03-08	2004-10-13	Nuvelo Inc	Methods and materials relating to fibulin-like polypeptides and polynucleotides
US7736654B2 (en)	2001-04-10	2010-06-15	Agensys, Inc.	Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
US7507413B2 (en)	2001-04-12	2009-03-24	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20030119112A1 (en)	2001-06-20	2003-06-26	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2002328853A1 (en) *	2001-07-06	2003-01-21	Geneprot, Inc.	Carcinoma-related peptides
US7176278B2 (en)	2001-08-30	2007-02-13	Biorexis Technology, Inc.	Modified transferrin fusion proteins
US8129504B2 (en)	2001-08-30	2012-03-06	Biorexis Technology, Inc.	Oral delivery of modified transferrin fusion proteins
AU2002332041A1 (en) *	2001-10-05	2003-04-22	Human Genome Sciences, Inc.	Albumin fusion proteins
DE10251673A1 (en)	2001-11-09	2003-07-10	Hoffmann La Roche	Alström syndrome gene, gene variants, encoded protein and method for diagnosing Alström syndrome
KR100406760B1 (en) *	2001-11-16	2003-11-21	신코엠 주식회사	Semiconductor memory device
CA2468790A1 (en)	2001-12-17	2003-06-26	Applied Research Systems Ars Holding N.V.	Chemokine mutants acting as chemokine antagonists
US20040082761A1 (en) *	2001-12-18	2004-04-29	Duggan Brendan M.	Cell adhesion proteins
AU2002364587A1 (en)	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060253913A1 (en) *	2001-12-21	2006-11-09	Yue-Jin Huang	Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20080194481A1 (en) *	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
KR101271635B1 (en) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	Albumin fusion proteins
PT1463751E (en) *	2001-12-21	2013-08-26	Human Genome Sciences Inc	Albumin fusion proteins
US7081446B2 (en) *	2002-01-31	2006-07-25	The Trustees Of Columbia University In The City Of New York	Long-acting follicle stimulating hormone analogues and uses thereof
CA2485064A1 (en) *	2002-02-07	2003-08-14	Delta Biotechnology Limited	Albumin-fused kunitz domain peptides
US20050222023A1 (en) *	2002-02-07	2005-10-06	Hans-Peter Hauser	Albumin-fused kunitz domain peptides
US20060241027A1 (en) *	2002-02-07	2006-10-26	Hans-Peter Hauser	Hiv inhibiting proteins
DE10205520A1 (en) *	2002-02-08	2003-08-14	Aventis Behring Gmbh	Inhibitory, monoclonal antibody against the clotting factor VII activating protease
BR0307871A (en) *	2002-02-21	2005-04-12	Wyeth Corp	Folistatin Domain-Containing Proteins
CA2477614A1 (en) *	2002-03-05	2003-09-18	Merck & Co., Inc.	Biomarker for efficacy of appetite suppressant drugs
US20030191056A1 (en)	2002-04-04	2003-10-09	Kenneth Walker	Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
AU2003225008A1 (en) *	2002-04-15	2003-11-03	American National Red Cross	Plasma protein-binding ligands
US20070015230A1 (en) *	2002-04-15	2007-01-18	Hammond David J	Identification and characterization of analytes from whole blood
US7319138B2 (en)	2002-04-18	2008-01-15	The General Hospital Corporation	Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
US7141381B2 (en)	2002-04-25	2006-11-28	Bristol-Myers Squibb Company	Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en) *	2002-05-08	2002-06-12	Svanborg Catharina	Therapeutic treatment
ATE528014T1 (en)	2002-06-07	2011-10-15	Dyax Corp	POLYPEPTIDE WITH MODIFIED KUNITZ DOMAINS
SI1531850T1 (en) *	2002-06-07	2012-07-31	Zymogenetics Inc	Use of IL-21 and monoclonal antibody for treating solid cancers
US7153829B2 (en)	2002-06-07	2006-12-26	Dyax Corp.	Kallikrein-inhibitor therapies
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en)	2002-06-20	2011-10-04	Paladin Labs, Inc.	Chimeric antigens for eliciting an immune response
CN1241946C (en) *	2002-07-01	2006-02-15	美国福源集团	Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
CN101172091B (en) *	2007-09-25	2011-04-27	北京美福源生物医药科技有限公司	Technique for preparing amalgamation protein skin-protection product containing albuminar and skin cell growth factor, and uses of the same
AU2003245090A1 (en) *	2002-07-03	2004-01-23	Nexgen Biotechnologies, Inc.	Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants
JP2006517384A (en) *	2002-07-08	2006-07-27	ジェネンテック・インコーポレーテッド	Compositions and methods for the treatment of immune related diseases
CA2493263A1 (en) *	2002-07-22	2004-01-29	Yamanouchi Pharmaceutical Co., Ltd.	Novel gene associated with rheumatoid arthritis
GB0217033D0 (en)	2002-07-23	2002-08-28	Delta Biotechnology Ltd	Gene and polypeptide sequences
WO2004015113A2 (en) *	2002-08-07	2004-02-19	Delta Biotechnology Ltd.	Albumin-fused ciliary neurotrophic factor
CN1674955A (en) *	2002-08-13	2005-09-28	阿尔比奥技术公司	Selective plasma exchange therapy
AU2003243413B2 (en)	2002-08-28	2009-07-09	Takeda Pharmaceutical Company Limited	Methods for preserving organs and tissues
US9415102B2 (en)	2002-09-06	2016-08-16	Alexion Pharmaceuticals, Inc.	High concentration formulations of anti-C5 antibodies
AU2003270330B2 (en) *	2002-09-06	2009-07-30	Alexion Pharmaceuticals, Inc.	Method of treatment of asthma using antibodies to complement component C5
US20050271660A1 (en)	2002-09-06	2005-12-08	Alexion Pharmaceuticals, Inc.	Nebulization of monoclonal antibodies for treating pulmonary diseases
EP1539959A2 (en) *	2002-09-18	2005-06-15	Centre Hospitalier de l'Université de Montréal (CHUM)	Ghrh analogues
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
DE10254601A1 (en)	2002-11-22	2004-06-03	Ganymed Pharmaceuticals Ag	Gene products differentially expressed in tumors and their use
ATE401346T1 (en) *	2002-12-20	2008-08-15	Geneos Oy	ASTHMA SENSITIVITY LOCATION
EP1577322A4 (en) *	2002-12-26	2006-01-25	Takeda Pharmaceutical	Novel proteins and use thereof
CA2513213C (en) *	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
PT1592786E (en) *	2003-02-11	2012-01-19	Shire Human Genetic Therapies	Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (fge)
CA2518912A1 (en) *	2003-03-12	2004-09-23	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7381410B2 (en) *	2003-03-12	2008-06-03	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2004082640A2 (en) *	2003-03-19	2004-09-30	New Century Pharmaceuticals, Inc.	Human serum albumin conjugates with therapeutic compounds
AU2004226162A1 (en) *	2003-04-04	2004-10-14	Universite De Lausanne	Peptabody for cancer treatment
ES2391087T3 (en)	2003-04-11	2012-11-21	Medimmune, Llc	Recombinant IL-9 antibodies and uses thereof
WO2004094589A2 (en) *	2003-04-18	2004-11-04	Incyte Corporation	Secreted proteins
US20050079546A1 (en) *	2003-05-01	2005-04-14	Dasa Lipovsek	Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en)	2003-05-07	2006-01-17	General Electric Company	Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
EP1650302B1 (en) *	2003-06-30	2012-03-21	Nihon University	Protein capable of deposition onto extracellular matrix
WO2005010040A1 (en)	2003-07-15	2005-02-03	Barros Research Institute	Eimeria tenella antigen for immunotherapy of coccidiosis
US8007805B2 (en) *	2003-08-08	2011-08-30	Paladin Labs, Inc.	Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) *	2003-09-05	2003-10-08	Celltech R&D Ltd	A protein involved in carcinoma
EP1694360B1 (en)	2003-11-04	2010-08-04	Novartis Vaccines and Diagnostics, Inc.	Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
US20080292581A1 (en) *	2003-12-03	2008-11-27	Delta Biotechnology Limited	Interleukin-11 Fusion Proteins
CN100379762C (en) *	2003-12-08	2008-04-09	中国人民解放军军事医学科学院生物工程研究所	Interfusion protein between human serum albumin and interleukin, and encoding genes
US9050378B2 (en)	2003-12-10	2015-06-09	Board Of Regents, The University Of Texas System	N2S2 chelate-targeting ligand conjugates
US7371381B2 (en)	2003-12-12	2008-05-13	Amgen Inc.	Anti-galanin antibodies and uses thereof
US9057061B2 (en)	2003-12-23	2015-06-16	Novozymes Biopharma Dk A/S	Gene expression technique
GB0329722D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Modified plasmid and use thereof
GB0329681D0 (en)	2003-12-23	2004-01-28	Delta Biotechnology Ltd	Gene expression technique
EP1712619A4 (en) *	2003-12-24	2008-01-02	Takeda Pharmaceutical	Preventive/remedy for cancer
DK1729795T3 (en) *	2004-02-09	2016-04-11	Human Genome Sciences Inc	Albumin fusion proteins
SE0400489D0 (en) *	2004-02-27	2004-02-27	Biovitrum Ab	Therapeutic proteins
WO2005085472A2 (en) *	2004-03-03	2005-09-15	Evotec Neurosciences Gmbh	Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
US20050201959A1 (en) *	2004-03-11	2005-09-15	Vvii Newco 2003, Inc.	Methods and compositions for altering skin coloration
JP2007528393A (en) *	2004-03-11	2007-10-11	カイセラバイオファーマシューティカルズ，インコーポレイテッド	Compositions and methods for preventing and treating skin conditions and hair conditions
DE602005025459D1 (en)	2004-03-12	2011-02-03	Vasgene Therapeutics Inc	EPHB4-Binding Antibodies for the Inhibition of Angiogenesis and Tumor Growth
AU2005247298B8 (en)	2004-04-14	2011-03-10	Avirid, Inc.	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
US7307148B2 (en) *	2004-04-23	2007-12-11	Conjuchem Biotechnologies Inc.	Method for purification of albumin conjugates
KR100599454B1 (en) *	2004-04-27	2006-07-12	재단법인서울대학교산학협력재단	3 Novel use of AIM3 acting as a tumor suppressor
DE102004024617A1 (en)	2004-05-18	2005-12-29	Ganymed Pharmaceuticals Ag	Differentially expressed in tumors gene products and their use
US8008020B2 (en) *	2004-06-03	2011-08-30	Vermillion, Inc.	Biomarkers for peripheral artery disease
US7906140B2 (en) *	2004-06-17	2011-03-15	Virun, Inc.	Compositions for mucosal delivery of agents
WO2006019904A1 (en)	2004-07-14	2006-02-23	University Of Utha Research Foundation	Netrin-related compositions and uses
KR20070052788A (en) *	2004-08-13	2007-05-22	밀레니엄 파머슈티컬스 인코퍼레이티드	Genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
WO2006034292A2 (en)	2004-09-21	2006-03-30	Medimmune, Inc.	Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006034455A2 (en)	2004-09-23	2006-03-30	Vasgene Therapeutics, Inc.	Polipeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) *	2004-09-27	2007-06-26	Dyax Corporation	Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US20060078541A1 (en) *	2004-10-01	2006-04-13	Giles Brian C	Method and formula for stem cells' stimulation, targeting release, trafficking and homing
AU2005295038B2 (en)	2004-10-06	2012-05-17	Mayo Foundation For Medical Education And Research	B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
WO2006042197A2 (en) *	2004-10-11	2006-04-20	The Board Of Trustees Of The Leland Standford Junior University	Use of del-1 in hair, bone and cartilage regeneration
ES2507094T3 (en)	2004-10-25	2014-10-14	Immune System Key Ltd.	Thymus specific protein
KR100583350B1 (en) *	2004-11-03	2006-06-05	(주)넥스젠	-1 Method for Producing Epidermal Growth Factor Using Fusion Proteins Comprising Fas-1 Domain
CN101087805B (en) *	2004-11-09	2012-05-23	阿雷斯贸易股份有限公司	Method for purifying FSH
EP2446897A1 (en)	2005-01-06	2012-05-02	Novo Nordisk A/S	Anti-KIR combination treatments and methods
US20060178301A1 (en) *	2005-02-04	2006-08-10	Mathias Jurs	Albumin-fused ciliary neurotrophic factor
PT1853718E (en)	2005-02-15	2015-11-12	Univ Duke	Anti-cd19 antibodies and uses in oncology
US20110230407A1 (en) *	2005-03-14	2011-09-22	Alexander Yuzhakov	Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
EP1864138A2 (en) *	2005-03-23	2007-12-12	Wyeth	Detection of gdf-8 modulating agents
MX2007011405A (en) *	2005-03-23	2007-10-11	Wyeth Corp	Detection of an immune response to gdf-8 modulating agents.
RU2412199C2 (en)	2005-04-18	2011-02-20	Ново Нордиск А/С	Versions of il-21
US7833979B2 (en) *	2005-04-22	2010-11-16	Amgen Inc.	Toxin peptide therapeutic agents
WO2006114115A1 (en)	2005-04-26	2006-11-02	Trion Pharma Gmbh	Combination of antibodies and glucocorticoids for treating cancer
US9345745B2 (en)	2005-04-29	2016-05-24	Bo Wang	Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US9585932B2 (en)	2005-04-29	2017-03-07	Peter C. Dowling	Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
WO2007052154A2 (en)	2005-04-29	2007-05-10	University Of Medicine And Dentistry Of New Jersey	Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
WO2006121852A2 (en)	2005-05-05	2006-11-16	Duke University	Anti-cd19 antibody therapy for autoimmune disease
CA2606334A1 (en) *	2005-05-12	2006-11-12	Zymogenetics, Inc.	Methods of using phhla2 to co-stimulate t-cells
EP2397155B1 (en)	2005-06-08	2017-12-13	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway
WO2007014167A2 (en) *	2005-07-22	2007-02-01	Five Prime Therapeutics, Inc.	Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) *	2005-08-01	2012-12-04	Allergan, Inc.	Botulinum toxin compositions
DK2573114T3 (en)	2005-08-10	2016-07-04	Macrogenics Inc	The identification and production of antibodies with variant Fc regions, and methods of using same
US8008453B2 (en)	2005-08-12	2011-08-30	Amgen Inc.	Modified Fc molecules
RS57549B1 (en) *	2005-08-26	2018-10-31	Ares Trading Sa	Process for the preparation of glycosylated interferon beta
US7713715B2 (en) *	2005-09-06	2010-05-11	University Of Tennessee Research Foundation	Method for diagnosing infections
US7846445B2 (en) *	2005-09-27	2010-12-07	Amunix Operating, Inc.	Methods for production of unstructured recombinant polymers and uses thereof
US20090099031A1 (en) *	2005-09-27	2009-04-16	Stemmer Willem P	Genetic package and uses thereof
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
US20070191272A1 (en) *	2005-09-27	2007-08-16	Stemmer Willem P	Proteinaceous pharmaceuticals and uses thereof
US20080274096A1 (en) *	2005-10-03	2008-11-06	Astrazeneca Ab	Fusion Proteins Having a Modulated Half-Life in Plasma
US8168592B2 (en) *	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
EP1790664A1 (en)	2005-11-24	2007-05-30	Ganymed Pharmaceuticals AG	Monoclonal antibodies against claudin-18 for treatment of cancer
JP5199112B2 (en) *	2005-12-09	2013-05-15	アレストレーディングソシエテアノニム	Method for purifying FSH or FSH variants
US20090304687A1 (en) *	2005-12-09	2009-12-10	Seattle Genetics , Inc.	Methods of using cd40 binding agents
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en)	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
AU2006329215A1 (en) *	2005-12-22	2007-06-28	Conjuchem Biotechnologies Inc.	Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090215084A1 (en) *	2006-01-05	2009-08-27	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
WO2007082144A2 (en) *	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and survivin in cancer
EP1989326A4 (en)	2006-01-17	2009-09-30	Health Research Inc	Heteroduplex tracking assay
EP1816201A1 (en)	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
WO2007097961A1 (en) *	2006-02-16	2007-08-30	Massachusetts Eye & Ear Infirmary	Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
EP2540741A1 (en)	2006-03-06	2013-01-02	Aeres Biomedical Limited	Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
KR20150064254A (en) *	2006-04-05	2015-06-10	애브비 바이오테크놀로지 리미티드	Antibody purification
AU2007236280B2 (en) *	2006-04-11	2013-07-25	Csl Behring Gmbh	Method of increasing the in vivo recovery of therapeutic polypeptides
WO2007124361A2 (en) *	2006-04-20	2007-11-01	Mayo Foundation For Medical Education And Research	Soluble b7-h1
US8334365B2 (en)	2006-06-07	2012-12-18	Human Genome Sciences, Inc.	Albumin fusion proteins
PL2032607T5 (en)	2006-06-14	2017-10-31	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP1867660A1 (en)	2006-06-14	2007-12-19	CSL Behring GmbH	Proteolytically cleavable fusion protein comprising a blood coagulation factor
AU2013202566C1 (en) *	2006-06-14	2018-07-12	Csl Behring Gmbh	Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en)	2006-06-14	2011-05-10	Csl Behring Gmbh	Proteolytically cleavable fusion proteins with high molar specific activity
CA2657277C (en) *	2006-07-13	2015-11-24	Upperton Limited	Process for preparing particles of proteinaceous material
EP2046826B1 (en)	2006-07-24	2011-09-14	Biorexis Pharmaceutical Corporation	Exendin fusion proteins
US20090208480A1 (en) *	2006-08-04	2009-08-20	Yue Huang	Long half-life recombinant butyrylcholinesterase
CN101578373A (en) *	2006-09-06	2009-11-11	费斯生物制药公司	Fusion peptide therapeutic compositions
MX2009002523A (en)	2006-09-08	2009-03-20	Ambrx Inc	Modified human plasma polypeptide or fc scaffolds and their uses.
US10925977B2 (en)	2006-10-05	2021-02-23	Ceil>Point, LLC	Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US7834164B2 (en) *	2006-10-25	2010-11-16	Amgen Inc.	DNA encoding OSK1 toxin peptide analogs and vectors and cells for combinant expression
US8475784B2 (en)	2006-10-26	2013-07-02	Novo Nordisk A/S	IL-21 variants
WO2008063382A2 (en)	2006-11-07	2008-05-29	Merck & Co., Inc.	Antagonists of pcsk9
KR20090098880A (en)	2006-12-12	2009-09-17	바이오렉시스 파마슈티칼 코포레이션	Transferrin fusion protein libraries
AU2007336243B2 (en)	2006-12-19	2012-07-26	Ablynx N.V.	Amino acid sequences directed against a metalloproteinase from the ADAM family and polypeptides comprising the same for the treatment of ADAM-related diseases and disorders
EP2115004A2 (en)	2006-12-19	2009-11-11	Ablynx N.V.	Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP3231440A1 (en)	2006-12-22	2017-10-18	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) *	2006-12-22	2008-06-25	CSL Behring GmbH	Modified coagulation factors with prolonged in vivo half-life
CA2677073C (en)	2007-01-30	2016-03-15	Epivax, Inc.	Regulatory t cell epitopes, compositions and uses thereof
EP2526962B1 (en)	2007-02-12	2019-08-14	CSL Behring GmbH	Therapeutic application of Kazal-type serine protease inhibitors
US8263353B2 (en)	2007-03-27	2012-09-11	Merck Sharp & Dohme Corp.	Method for detecting autoprocessed, secreted PCSK9
MX2009011996A (en)	2007-05-07	2010-04-21	Medimmune Llc	Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease.
US20100291073A1 (en)	2007-05-14	2010-11-18	Medimmune, Llc	Methods of reducing eosinophil levels
MX2009012609A (en) *	2007-05-22	2009-12-07	Amgen Inc	Compositions and methods for producing bioactive fusion proteins.
EP1997830A1 (en)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	RSV specific binding molecules and means for producing them
EP2170946A2 (en)	2007-07-13	2010-04-07	The Johns Hopkins University	B7-dc variants
US20100268055A1 (en) *	2007-07-19	2010-10-21	Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University	Self-Anchoring MEMS Intrafascicular Neural Electrode
BRPI0815416A2 (en) *	2007-08-15	2014-10-21	Amunix Inc	COMPOSITIONS AND METHODS FOR MODIFYING PROPERTIES OF BIOLOGICALLY ACTIVE POLYPEPTIDES
MX338474B (en)	2007-08-29	2016-04-18	Sanofi Aventis	Humanized anti-cxcr5 antibodies, derivatives thereof and their uses.
JP2009055838A (en) *	2007-08-31	2009-03-19	Nipro Corp	Fusion protein, gene related to the fusion protein, vector, transformant and anti-inflammatory medicinal composition
MX349306B (en) *	2007-09-21	2017-07-19	Univ California	Targeted interferon demonstrates potent apoptotic and anti-tumor activities.
EP2050764A1 (en)	2007-10-15	2009-04-22	sanofi-aventis	Novel polyvalent bispecific antibody format and uses thereof
CA2701221A1 (en) *	2007-10-22	2009-04-30	Merck Serono S.A.	Method for purifying an fc-containing protein
EP2203474A1 (en) *	2007-10-22	2010-07-07	Merck Serono S.A.	Method for purifying fc-fusion proteins
EP2225275A4 (en)	2007-11-28	2013-04-03	Medimmune Llc	Protein formulation
EP2604628A3 (en)	2007-12-21	2013-08-21	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4R) - 173
US8092804B2 (en)	2007-12-21	2012-01-10	Medimmune Limited	Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
US20100311072A1 (en) *	2008-01-28	2010-12-09	Bristol-Myers Squibb Company	Fluorescence polarization binding assay for characterizing glucokinase ligands
AR070315A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	ANTIBODIES 1B20 ANTAGONISTS OF PCSK9
AR070316A1 (en)	2008-02-07	2010-03-31	Merck & Co Inc	PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN)
WO2009111315A2 (en) *	2008-02-29	2009-09-11	Mayo Foundation For Medical Education And Research	Methods for reducing granulomatous inflammation
JP5020135B2 (en) *	2008-03-19	2012-09-05	ソニーモバイルコミュニケーションズ，エービー	Portable terminal device and computer program
CN102065903B (en)	2008-04-01	2015-02-18	诺沃-诺迪斯克有限公司	Insulin albumin conjugates
EP2260058A2 (en)	2008-04-07	2010-12-15	Ablynx N.V.	Single variable domains against the notch pathways
EP2274331B1 (en)	2008-05-02	2013-11-06	Novartis AG	Improved fibronectin-based binding molecules and uses thereof
AU2013202564B2 (en) *	2008-06-24	2015-09-17	Csl Behring Gmbh	Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
ES2654336T3 (en) *	2008-06-24	2018-02-13	Csl Behring Gmbh	Factor VIII, von Willebrand factor or its complexes with prolonged in vivo half-life
CN105727261A (en)	2008-06-27	2016-07-06	杜克大学	Therapeutic agents comprising elastic peptides
CA2767331A1 (en) *	2008-07-10	2010-01-14	Angion Biomedica Corp.	Methods and compositions of small molecule modulators of hepatocyte growth factor (scatter factor) activity
AU2009273251B2 (en)	2008-07-22	2014-12-18	Ablynx Nv	Amino acid sequences directed against multitarget scavenger receptors and polypeptides
NZ600622A (en)	2008-08-05	2013-12-20	Novartis Ag	Compositions and methods for antibodies targeting complement protein c5
EA201500417A1 (en)	2008-08-25	2015-11-30	Эмплиммьюн, Инк.	ANTAGONIST COMPOSITIONS PD-1 AND APPLICATIONS
EA201170375A1 (en) *	2008-08-25	2012-03-30	Эмплиммьюн, Инк.	PD-1 ANTAGONISTS AND METHODS OF THEIR APPLICATION
EP2324060B1 (en)	2008-09-07	2015-07-22	Glyconex Inc.	Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
US20110293605A1 (en)	2008-11-12	2011-12-01	Hasige Sathish	Antibody formulation
CN102282168A (en) *	2008-11-18	2011-12-14	梅里麦克制药股份有限公司	Human serum albumin linkers and conjugates thereof
KR101721707B1 (en)	2008-11-28	2017-03-30	에모리 유니버시티	Methods for the treatment of infections and tumors
HRP20240240T1 (en)	2008-12-09	2024-04-26	F. Hoffmann - La Roche Ag	Anti-pd-l1 antibodies and their use to enhance t-cell function
WO2010068526A1 (en)	2008-12-12	2010-06-17	Merck Sharp & Dohme Corp.	Pcsk9 immunoassay
CA2744235A1 (en)	2009-01-06	2010-07-15	Dyax Corp.	Treatment of mucositis with kallikrein inhibitors
US20100227818A1 (en)	2009-01-16	2010-09-09	Teva Biopharmaceuticals Usa, Inc.	Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor For The Prevention Of Neutropenia
WO2010087927A2 (en)	2009-02-02	2010-08-05	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8680050B2 (en) *	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
MX2011008094A (en)	2009-02-03	2012-02-13	Amunix Operating Inc	Extended recombinant polypeptides and compositions comprising same.
US8703717B2 (en) *	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
KR101722961B1 (en)	2009-02-11	2017-04-04	알부메딕스 에이/에스	Albumin variants and conjugates
WO2010108154A2 (en)	2009-03-20	2010-09-23	Amgen Inc.	Selective and potent peptide inhibitors of kv1.3
WO2010128142A1 (en)	2009-05-07	2010-11-11	Novozymes Biopharma Dk A/S	Method for purifying albumin
EP2258398A1 (en) *	2009-05-26	2010-12-08	Araclón Biotech, S. L.	Albumin-amyloid peptide conjugates and uses thereof
WO2010138555A2 (en) *	2009-05-26	2010-12-02	University Of Florida Research Foundation, Inc.	Small peptide expression system in mammalian cells
CA2764108A1 (en) *	2009-06-08	2010-12-16	Amunix Operating Inc.	Glucose-regulating polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
CN101628346B (en) *	2009-07-25	2012-05-16	大连理工大学	Method for slowing down outlet speed of carbon fiber composite material hand-made hole and buffer device thereof
JP5883384B2 (en)	2009-08-13	2016-03-15	ザジョンズホプキンスユニバーシティー	How to regulate immune function
JP6250282B2 (en)	2009-08-20	2017-12-20	ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー	Albumin fusion clotting factor for non-intravenous administration in the treatment and prophylactic treatment of bleeding disorders
US9173817B2 (en)	2009-08-24	2015-11-03	Arsenal Medical, Inc.	In situ forming hemostatic foam implants
US9044580B2 (en)	2009-08-24	2015-06-02	Arsenal Medical, Inc.	In-situ forming foams with outer layer
US20110202016A1 (en) *	2009-08-24	2011-08-18	Arsenal Medical, Inc.	Systems and methods relating to polymer foams
AU2010290131C1 (en)	2009-08-24	2015-12-03	Amunix Operating Inc.	Coagulation factor VII compositions and methods of making and using same
US10420862B2 (en)	2009-08-24	2019-09-24	Aresenal AAA, LLC.	In-situ forming foams for treatment of aneurysms
US8451450B2 (en) *	2009-09-14	2013-05-28	Bio-Rad Laboratories, Inc.	Near real time optical phase conjugation
US20110172398A1 (en)	2009-10-02	2011-07-14	Boehringer Ingelheim International Gmbh	Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (en)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	DLL-4 BINDING MOLECULES
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
DK2486141T3 (en)	2009-10-07	2018-04-23	Macrogenics Inc	FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE
US20120322075A1 (en) *	2009-10-26	2012-12-20	Externautics S.P.A.	Lung Tumor Markers and Methods of Use Thereof
EP2493507A4 (en)	2009-10-30	2013-11-20	Merck Sharp & Dohme	Ax213 and ax132 pcsk9 antagonists and variants
CN105567699A (en)	2009-10-30	2016-05-11	诺维信生物制药丹麦公司	Albumin variants
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
CN102596249A (en)	2009-10-30	2012-07-18	默沙东公司	AX1 and AX189 PCSK9 antagonists and variants
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
EP2501714A4 (en) *	2009-11-17	2015-10-07	Univ Montreal	Heteropeptides useful for reducing nonspecific adsorption
SI2506868T1 (en) *	2009-12-06	2018-04-30	Bioverativ Therapeutics Inc.	Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
CA2782838A1 (en)	2009-12-08	2011-06-16	Teva Pharmaceutical Industries Ltd.	Bche albumin fusions for the treatment of cocaine abuse
US8962807B2 (en)	2009-12-14	2015-02-24	Ablynx N.V.	Single variable domain antibodies against OX40L, constructs and therapeutic use
WO2011084145A2 (en)	2009-12-21	2011-07-14	Pharmathene, Inc.	Recombinant butyrylcholinesterases and truncates thereof
HUE057244T2 (en)	2010-01-06	2022-04-28	Takeda Pharmaceuticals Co	Plasma kallikrein binding proteins
TWI513466B (en)	2010-01-20	2015-12-21	Boehringer Ingelheim Int	Anticoagulant antidotes
TWI508737B (en)	2010-01-22	2015-11-21	諾佛儂迪克股份有限公司	Growth hormones with prolonged in-vivo efficacy
JP5980689B2 (en)	2010-01-22	2016-08-31	ノヴォ・ノルディスク・ヘルス・ケア・アーゲー	Stable growth hormone compound
WO2011092233A1 (en)	2010-01-29	2011-08-04	Novartis Ag	Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en)	2010-02-10	2015-09-01	Novartis Ag	Biologic compounds directed against death receptor 5
EP2547328B1 (en) *	2010-02-11	2017-06-07	Ecole Polytechnique Fédérale de Lausanne (EPFL)	Ccr7 ligand delivery and co-delivery in immunotherapy
TW201144437A (en)	2010-03-03	2011-12-16	Boehringer Ingelheim Int	A-beta binding polypeptides
EP2371857A1 (en)	2010-04-01	2011-10-05	CSL Behring GmbH	Factor XII inhibitors for treating interstitial lung disease
CN106977608A (en)	2010-04-09	2017-07-25	阿尔布麦狄克斯公司	Albumin derivant and variant
SG185416A1 (en)	2010-05-06	2012-12-28	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
AU2011249782B2 (en)	2010-05-06	2014-10-02	Novartis Ag	Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
RU2012149227A (en)	2010-05-20	2014-06-27	Аблинкс Нв	BIOLOGICAL MATERIALS RELATING TO HER3
SG10201505218YA (en)	2010-07-09	2015-08-28	Biogen Hemophilia Inc	Factor ix polypeptides and methods of use thereof
EP3508573A1 (en)	2010-07-09	2019-07-10	Bioverativ Therapeutics Inc.	Systems for factor viii processing and methods thereof
WO2012019061A2 (en)	2010-08-05	2012-02-09	Stem Centrx, Inc.	Novel effectors and methods of use
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
US9518087B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9517257B2 (en)	2010-08-10	2016-12-13	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
US9850296B2 (en)	2010-08-10	2017-12-26	Ecole Polytechnique Federale De Lausanne (Epfl)	Erythrocyte-binding therapeutics
AU2011290672B2 (en)	2010-08-20	2015-07-09	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3)
KR20140018837A (en)	2010-08-27	2014-02-13	스템 센트알엑스 인코포레이티드	Notum protein modulators and methods of use
AU2011295715B9 (en)	2010-09-03	2017-02-23	Abbvie Stemcentrx Llc	Novel modulators and methods of use
US20120225081A1 (en)	2010-09-03	2012-09-06	Boehringer Ingelheim International Gmbh	Vegf-binding molecules
JP6159660B2 (en)	2010-09-22	2017-07-05	アムジエン・インコーポレーテツド	Immunoglobulins as carriers and uses thereof
MX349054B (en) *	2010-09-28	2017-07-07	Aegerion Pharmaceuticals Inc	Highly soluble leptins.
PT3590949T (en)	2010-10-01	2022-08-02	Modernatx Inc	Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
US8892184B2 (en)	2010-10-18	2014-11-18	Siemens Medical Solutions Usa, Inc.	Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) *	2010-10-26	2014-10-07	Pioneer Hi Bred International Inc	Antifungal proteins and methods of use
CN103347893A (en)	2010-11-01	2013-10-09	诺维信生物制药丹麦公司	Albumin variants
CN103429620B (en)	2010-11-05	2018-03-06	酵活有限公司	There is the antibody design of the stable heterodimeric of mutation in Fc domains
CA3239880A1 (en)	2010-11-08	2012-05-18	Ablynx N.V.	Cxcr2 binding polypeptides
US9066974B1 (en)	2010-11-13	2015-06-30	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
US9095606B1 (en)	2010-11-13	2015-08-04	Sirbal Ltd.	Molecular and herbal combinations for treating psoriasis
EP2643353A1 (en)	2010-11-24	2013-10-02	Novartis AG	Multispecific molecules
NZ728016A (en)	2010-12-08	2020-06-26	Abbvie Stemcentrx Llc	Novel modulators and methods of use
EP2660600B1 (en)	2010-12-28	2018-08-08	Sumitomo Dainippon Pharma Co., Ltd.	Diagnostic drug and diagnostic method for alzheimer's disease
US20120171195A1 (en)	2011-01-03	2012-07-05	Ravindranath Mepur H	Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
KR102107695B1 (en)	2011-01-06	2020-05-07	다이액스 코포레이션	Plasma kallikrein binding proteins
SA112330278B1 (en)	2011-02-18	2015-10-09	ستيم سينتركس، انك.	Novel modulators and methods of use
EP2681238A2 (en)	2011-02-28	2014-01-08	Istituto di Ricovero E Cura A Carattere Scientifico Materno-Infantile Burlo Garofolo- Ospedale di Alta Specializzazione E di Rilievo	Apoptosis-inducing molecules and uses therefor
US9499605B2 (en)	2011-03-03	2016-11-22	Zymeworks Inc.	Multivalent heteromultimer scaffold design and constructs
DK2683397T3 (en)	2011-03-09	2017-09-18	Csl Behring Gmbh	FACTOR XII INHIBITORS FOR ADMINISTRATION OF MEDICAL PROCEDURES COMPREHENSIVE CONTACT WITH ARTIFICIAL SURFACES
EP2497489A1 (en)	2011-03-09	2012-09-12	CSL Behring GmbH	Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
EP2686014A1 (en)	2011-03-16	2014-01-22	Sanofi	Uses of a dual v region antibody-like protein
SG10201601789TA (en)	2011-03-16	2016-04-28	Amgen Inc	Potent And Selective Inhibitors Of Nav1.3 And Nav1.7
WO2012135500A1 (en)	2011-03-29	2012-10-04	The General Hospital Corporation	Engineered thioredoxin-like fold proteins
CN103476459A (en)	2011-03-30	2013-12-25	勃林格殷格翰国际有限公司	Antidotes for anticoagulants
EP2691101A2 (en)	2011-03-31	2014-02-05	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US20130078247A1 (en)	2011-04-01	2013-03-28	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en)	2011-04-01	2016-12-27	Boehringer Ingelheim International Gmbh	Bispecific binding molecules binding to VEGF and ANG2
RU2623161C2 (en)	2011-04-15	2017-06-22	Компуджен Лтд.	Polypeptides and polynucleotides and their use for treatment of immune disorders and cancer
EP2515112B1 (en) *	2011-04-22	2015-08-12	Sysmex Corporation	Method for electrochemically detecting analyte
EP2702077A2 (en)	2011-04-27	2014-03-05	AbbVie Inc.	Methods for controlling the galactosylation profile of recombinantly-expressed proteins
UA117218C2 (en)	2011-05-05	2018-07-10	Мерк Патент Гмбх	Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same
WO2012150319A1 (en)	2011-05-05	2012-11-08	Novozymes Biopharma Dk A/S	Albumin variants
US9561274B2 (en)	2011-06-07	2017-02-07	University Of Hawaii	Treatment and prevention of cancer with HMGB1 antagonists
US9244074B2 (en)	2011-06-07	2016-01-26	University Of Hawaii	Biomarker of asbestos exposure and mesothelioma
DK2717898T3 (en)	2011-06-10	2019-03-25	Bioverativ Therapeutics Inc	COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF
WO2012172495A1 (en)	2011-06-14	2012-12-20	Novartis Ag	Compositions and methods for antibodies targeting tem8
US20160145589A1 (en)	2011-06-24	2016-05-26	Green Cross Corporation	Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
CN110066340B (en)	2011-06-28	2024-06-25	英伊布里克斯公司	Serine protease inhibitor protein fusion polypeptides and methods of use thereof
CA2840552A1 (en)	2011-07-01	2013-01-10	Bayer Intellectual Property Gmbh	Relaxin fusion polypeptides and uses thereof
US10844349B2 (en)	2011-07-05	2020-11-24	Albumedix Ltd.	Albumin formulation and use
CA2840944A1 (en)	2011-07-08	2013-01-17	Bayer Intellectual Property Gmbh	Fusion proteins releasing relaxin and uses thereof
EP2729160B1 (en)	2011-07-08	2019-03-27	Aegerion Pharmaceuticals, Inc.	Engineered polypeptides having enhanced duration of action and reduced immunogenicity
AU2012286048A1 (en) *	2011-07-18	2014-02-20	Arts Biologics A/S	Long acting luteinizing hormone (LH) compound
US9518127B2 (en)	2011-07-22	2016-12-13	Csl Behring Gmbh	Inhibitory anti-factor XII/XIIA monoclonal antibodies and their uses
US20130058947A1 (en)	2011-09-02	2013-03-07	Stem Centrx, Inc	Novel Modulators and Methods of Use
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
RU2648950C2 (en)	2011-10-03	2018-04-02	Модерна Терапьютикс, Инк.	Modified nucleosides, nucleotides and nucleic acids and their application
WO2013067060A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
US8993831B2 (en) *	2011-11-01	2015-03-31	Arsenal Medical, Inc.	Foam and delivery system for treatment of postpartum hemorrhage
WO2013067057A1 (en)	2011-11-01	2013-05-10	Bionomics, Inc.	Anti-gpr49 antibodies
JP2014533247A (en)	2011-11-01	2014-12-11	バイオノミクスインコーポレイテッド	Antibodies and methods of treating cancer
AU2012332588B2 (en)	2011-11-01	2017-09-07	Bionomics, Inc.	Methods of blocking cancer stem cell growth
CN104039830A (en)	2011-11-04	2014-09-10	诺华股份有限公司	Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
HUE056462T2 (en)	2011-11-04	2022-02-28	Zymeworks Inc	Stable heterodimeric antibody design with mutations in the fc domain
WO2013075066A2 (en)	2011-11-18	2013-05-23	Eleven Biotherapeutics, Inc.	Proteins with improved half-life and other properties
AU2012349736A1 (en)	2011-12-05	2014-06-26	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
SG11201402783YA (en)	2011-12-05	2014-06-27	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3)
RS63244B1 (en)	2011-12-16	2022-06-30	Modernatx Inc	Modified mrna compositions
EP2794656B1 (en)	2011-12-21	2019-02-27	Novartis AG	Compositions comprising antibodies targeting factor p and c5
AU2012318275B2 (en)	2011-12-22	2016-05-19	Csl Behring Gmbh	Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
US10800847B2 (en)	2012-01-11	2020-10-13	Dr. Mepur Ravindranath	Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
US20130177574A1 (en)	2012-01-11	2013-07-11	Paul I. Terasaki Foundation Laboratory	ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
EA035323B1 (en)	2012-01-12	2020-05-28	Биовератив Терапьютикс Инк.	Chimeric factor viii polypeptides and uses thereof
EP2623110A1 (en)	2012-01-31	2013-08-07	CSL Behring GmbH	Factor XII inhibitors for the treatment of neurological inflammatory disorders
JP6383666B2 (en)	2012-02-15	2018-08-29	バイオベラティブセラピューティクスインコーポレイテッド	Recombinant factor VIII protein
PL2814502T3 (en) *	2012-02-15	2018-02-28	Csl Behring Gmbh	Von willebrand factor variants having improved factor viii binding affinity
HRP20221531T1 (en)	2012-02-15	2023-02-17	Bioverativ Therapeutics Inc.	Factor viii compositions and methods of making and using same
AU2013220079B2 (en)	2012-02-15	2017-10-05	Ecole Polytechnique Federale De Lausanne	Erythrocyte-binding therapeutics
EP2817338B1 (en)	2012-02-24	2017-07-26	AbbVie Stemcentrx LLC	Dll3 modulators and methods of use
CA2862182A1 (en)	2012-02-27	2013-09-06	Boehringer Ingelheim International Gmbh	Cx3cr1-binding polypeptides
CA2861592A1 (en)	2012-03-16	2013-09-19	Novozymes Biopharma Dk A/S	Albumin variants
GB201204868D0 (en) *	2012-03-20	2012-05-02	San Raffaele Centro Fond	Peptides
US9592289B2 (en)	2012-03-26	2017-03-14	Sanofi	Stable IgG4 based binding agent formulations
CA2862516C (en)	2012-03-27	2023-02-14	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
WO2013151664A1 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of proteins
US9303079B2 (en)	2012-04-02	2016-04-05	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9067990B2 (en)	2013-03-14	2015-06-30	Abbvie, Inc.	Protein purification using displacement chromatography
US9505833B2 (en)	2012-04-20	2016-11-29	Abbvie Inc.	Human antibodies that bind human TNF-alpha and methods of preparing the same
US9181572B2 (en)	2012-04-20	2015-11-10	Abbvie, Inc.	Methods to modulate lysine variant distribution
US9334319B2 (en)	2012-04-20	2016-05-10	Abbvie Inc.	Low acidic species compositions
IN2014MN02164A (en) *	2012-04-27	2015-08-28	Cytomx Therapeutics Inc
WO2013166290A1 (en)	2012-05-04	2013-11-07	Abbvie Biotherapeutics Inc.	P21 biomarker assay
US9328174B2 (en)	2012-05-09	2016-05-03	Novartis Ag	Chemokine receptor binding polypeptides
WO2013167153A1 (en)	2012-05-09	2013-11-14	Ganymed Pharmaceuticals Ag	Antibodies useful in cancer diagnosis
JP6351572B2 (en)	2012-05-10	2018-07-04	ザイムワークス，インコーポレイテッド	Heteromultimeric constructs of immunoglobulin heavy chains with mutations in the Fc domain
WO2013177386A1 (en)	2012-05-24	2013-11-28	Abbvie Biotherapeutics Inc.	Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
WO2013176754A1 (en)	2012-05-24	2013-11-28	Abbvie Inc.	Novel purification of antibodies using hydrophobic interaction chromatography
CN104507317B (en)	2012-05-30	2019-11-15	拜尔农作物科学股份公司	Composition comprising biocontrol agent and fungicide, and application thereof, kit
NZ702162A (en)	2012-05-30	2016-11-25	Bayer Cropscience Ag	Compositions comprising a biological control agent and an insecticide
IN2014DN09381A (en)	2012-05-30	2015-07-17	Bayer Cropscience Ag
EP2854532B1 (en)	2012-05-30	2019-08-07	Bayer Cropscience AG	Compositions comprising a biological control agent and an insecticide
CN104507311A (en)	2012-05-30	2015-04-08	拜尔农作物科学股份公司	Compositions comprising a biological control agent and an insecticide
WO2013178649A1 (en)	2012-05-30	2013-12-05	Bayer Cropscience Ag	Compositions comprising a biological control agent and a fungicide from the group consisting of inhibitors of the respiratory chain at complex i or ii.
PT2854547T (en)	2012-05-30	2018-11-16	Bayer Cropscience Ag	Composition comprising a biological control agent and trifloxystrobin
AR091816A1 (en)	2012-05-30	2015-03-04	Bayer Cropscience Ag	COMPOSITION THAT INCLUDES A BIOLOGICAL CONTROL AGENT AND AN INSECTICIDE
PL2854546T3 (en)	2012-05-30	2019-03-29	Bayer Cropscience Ag	Composition comprising a biological control agent and a fungicide selected from inhibitors of the ergosterol biosynthesis
EP2854549B1 (en)	2012-05-30	2018-08-01	Bayer Cropscience AG	Composition comprising a biological control agent and fluopicolide
AR091200A1 (en)	2012-05-30	2015-01-21	Bayer Cropscience Ag	COMPOSITION THAT INCLUDES A BIOLOGICAL CONTROL AGENT AND A FUNGICIDE
TR201816272T4 (en)	2012-05-30	2018-11-21	Bayer Cropscience Ag	The composition comprising a biological control agent and flopicolide.
EP2863940A4 (en)	2012-06-08	2016-08-10	Biogen Ma Inc	Chimeric clotting factors
AU2013270682A1 (en)	2012-06-08	2014-12-11	Biogen Ma Inc.	Procoagulant compounds
US9150841B2 (en)	2012-06-29	2015-10-06	Shire Human Genetic Therapies, Inc.	Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (en)	2012-06-29	2014-04-11	쉐어 휴먼 제네텍 세러피스, 인코포레이티드	Purification of iduronate-2-sulfatase
US10656156B2 (en)	2012-07-05	2020-05-19	Mepur Ravindranath	Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
CN110054699A (en)	2012-07-11	2019-07-26	比奥贝拉蒂治疗公司	Factor IX compound with XTEN and vWF ELISA albumen, and application thereof
JP6498601B2 (en)	2012-07-13	2019-04-10	ザイムワークス，インコーポレイテッド	Multivalent heteromultimeric scaffold designs and constructs
US20150202287A1 (en)	2012-08-30	2015-07-23	Merrimack Pharmaceuticals, Inc.	Combination therapies comprising anti-erbb3 agents
BR112015004467A2 (en)	2012-09-02	2017-03-21	Abbvie Inc	method for controlling protein heterogeneity
US9512214B2 (en)	2012-09-02	2016-12-06	Abbvie, Inc.	Methods to control protein heterogeneity
US10391152B2 (en)	2012-10-18	2019-08-27	Bioverativ Therapeutics Inc.	Methods of using a fixed dose of a clotting factor
CA2890766A1 (en)	2012-11-08	2014-05-15	Novozymes Biopharma Dk A/S	Albumin variants
RU2678127C2 (en)	2012-11-13	2019-01-23	Бионтех Аг	Agents for treatment of claudin expressing cancer diseases
RS63237B1 (en)	2012-11-26	2022-06-30	Modernatx Inc	Terminally modified rna
WO2014084859A1 (en)	2012-11-30	2014-06-05	Novartis Ag	Molecules and methods for modulating tmem16a activities
RS61648B1 (en)	2012-12-05	2021-04-29	Novartis Ag	Compositions and methods for antibodies targeting epo
US20160067347A1 (en)	2012-12-20	2016-03-10	Amgen Inc.	Apj receptor agonists and uses thereof
WO2014113359A1 (en)	2013-01-15	2014-07-24	Teva Pharmaceutical Industries Ltd.	Formulations of albu-bche, preparation and uses thereof
KR101503907B1 (en) *	2013-01-17	2015-03-20	서울대학교산학협력단	Recombinant protein vaccine for preventing Actinobacillus pleuropneumoniae and Mycoplasma hyopneumoniae infection diseases
KR101993714B1 (en)	2013-01-30	2019-06-28	엔지엠 바이오파마슈티컬스, 아이엔씨.	Compositions and methods of use in treating metabolic disorders
US9161966B2 (en)	2013-01-30	2015-10-20	Ngm Biopharmaceuticals, Inc.	GDF15 mutein polypeptides
US20140302986A1 (en)	2013-02-11	2014-10-09	Bayer Cropscience Lp	Compositions comprising a streptomyces-based biological control agent and another biological control agent
DK3889173T5 (en)	2013-02-15	2024-08-05	Bioverativ Therapeutics Inc	OPTIMIZED FACTOR VIII GENE
DK2956002T3 (en)	2013-02-16	2017-12-11	Albumedix As	Pharmacokinetic animal model
EP2961422B1 (en)	2013-02-28	2016-09-28	CSL Behring GmbH	Therapeutic agent for amniotic fluid embolism
US9255262B2 (en) *	2013-03-06	2016-02-09	Vision Global Holdings Ltd.	Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en)	2013-03-06	2021-11-02	Vision Global Holdings Ltd.	Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
WO2014135694A1 (en)	2013-03-08	2014-09-12	Csl Behring Ag	Treatment and prevention of remote ischemia-reperfusion injury
US10981961B2 (en)	2013-03-11	2021-04-20	University Of Florida Research Foundation, Incorporated	Delivery of card protein as therapy for occular inflammation
UY35397A (en)	2013-03-12	2014-10-31	Amgen Inc	POWERFUL AND SELECTIVE INHIBITORS OF NaV1.7
US20160024181A1 (en) *	2013-03-13	2016-01-28	Moderna Therapeutics, Inc.	Long-lived polynucleotide molecules
US20160152686A1 (en)	2013-03-13	2016-06-02	Bristol-Myers Squibb Company	Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
US9499614B2 (en)	2013-03-14	2016-11-22	Abbvie Inc.	Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en)	2013-03-14	2014-10-02	Abbvie Inc.	MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en)	2013-10-18	2015-04-28	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
WO2014159239A2 (en)	2013-03-14	2014-10-02	Novartis Ag	Antibodies against notch 3
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
SG11201505926VA (en)	2013-03-15	2015-09-29	Biogen Ma Inc	Factor ix polypeptide formulations
US20160051673A1 (en)	2013-03-29	2016-02-25	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
EP2981282B1 (en) *	2013-04-05	2020-11-04	Novo Nordisk Health Care AG	Growth hormone compound formulation
DK2796145T3 (en)	2013-04-22	2018-01-29	Csl Ltd	A covalent complex of von Willebrand factor and factor VIII linked by a disulfide bridge
AR096601A1 (en)	2013-06-21	2016-01-20	Novartis Ag	ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
UY35620A (en)	2013-06-21	2015-01-30	Novartis Ag	ANTIBODIES OF LEXINED OXIDATED LDL RECEIVER 1 AND METHODS OF USE
JP2016523919A (en)	2013-06-28	2016-08-12	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Thrombin cleavable linker having XTEN and use thereof
CN105339010A (en)	2013-06-28	2016-02-17	德国杰特贝林生物制品有限公司	Combination therapy using a factor XII inhibitor and a C1-inhibitor
CN104342420B (en) *	2013-07-30	2017-09-15	惠觅宙	A kind of recombinant long-acting people hyaluronidase, its encoding gene, production method and application
TW202003554A (en)	2013-08-14	2020-01-16	美商百歐維拉提夫治療公司	Factor VIII-XTEN fusions and uses thereof
EP4108254A1 (en)	2013-08-14	2022-12-28	Bioverativ Therapeutics Inc.	Recombinant factor viii proteins
US9579257B2 (en)	2013-08-20	2017-02-28	Anutra Medical, Inc.	Haptic feedback and audible output syringe
RU2016111139A (en)	2013-08-28	2017-10-03	ЭББВИ СТЕМСЕНТРКС ЭлЭлСи	NEW SEZ6 MODULATORS AND WAYS OF THEIR APPLICATION
SG11201601424PA (en)	2013-08-28	2016-03-30	Stemcentrx Inc	Site-specific antibody conjugation methods and compositions
EP3903599A1 (en)	2013-09-25	2021-11-03	Bioverativ Therapeutics Inc.	On-column viral inactivation methods
CN103468662A (en) *	2013-09-29	2013-12-25	惠觅宙	Recombined human hyaluronidase, production and purification method and preparations thereof, use method and application
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
EP3470081A1 (en)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Methods for treating cancer in patients with elevated levels of bim
WO2015051214A1 (en)	2013-10-03	2015-04-09	Moderna Therapeutics, Inc.	Polynucleotides encoding low density lipoprotein receptor
US9598667B2 (en)	2013-10-04	2017-03-21	Abbvie Inc.	Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) *	2013-10-17	2015-04-23	Tarix Pharmaceuticals Ltd.	Compositions and methods for treatment of inflammatory bowel disease
US8946395B1 (en)	2013-10-18	2015-02-03	Abbvie Inc.	Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en)	2013-10-18	2015-11-10	Abbvie, Inc.	Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en)	2013-10-18	2015-07-21	Abbvie, Inc.	Low acidic species compositions and methods for producing and using the same
US9540440B2 (en)	2013-10-30	2017-01-10	Cytomx Therapeutics, Inc.	Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
EP3063275B1 (en)	2013-10-31	2019-09-25	Resolve Therapeutics, LLC	Therapeutic nuclease-albumin fusions and methods
JP6306700B2 (en) *	2013-11-01	2018-04-04	ユニバーシティオブオスロＵｎｉｖｅｒｓｉｔｙｏｆＯｓｌｏ	Modified albumin and use thereof
WO2015070014A1 (en)	2013-11-08	2015-05-14	Biogen Idec Ma Inc.	Procoagulant fusion compound
WO2015073884A2 (en)	2013-11-15	2015-05-21	Abbvie, Inc.	Glycoengineered binding protein compositions
US9737623B2 (en)	2013-12-11	2017-08-22	Cytomx Therapeutics, Inc.	Antibodies that bind activatable antibodies and methods of use thereof
US8986691B1 (en)	2014-07-15	2015-03-24	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en)	2014-07-15	2015-03-17	Kymab Limited	Method of treating atopic dermatitis or asthma using antibody to IL4RA
ES2902835T3 (en)	2014-01-09	2022-03-30	Hadasit Med Res Service	Improved cell compositions and methods for cancer therapy
PT4176894T (en)	2014-01-10	2024-05-21	Bioverativ Therapeutics Inc	Factor viii chimeric proteins and uses thereof
US10046056B2 (en)	2014-02-21	2018-08-14	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
US10953101B2 (en)	2014-02-21	2021-03-23	École Polytechnique Fédérale De Lausanne (Epfl)	Glycotargeting therapeutics
KR20240154672A (en)	2014-02-21	2024-10-25	에꼴 뽈리떼끄닉 뻬데랄 드 로잔느 (으뻬에프엘)	Glycotargeting therapeutics
US10946079B2 (en)	2014-02-21	2021-03-16	Ecole Polytechnique Federale De Lausanne	Glycotargeting therapeutics
EP3116898B1 (en)	2014-03-11	2022-01-26	University of Florida Research Foundation, Inc.	Aav-expressed m013 protein as an anti-inflammatroy therapeutic for use in a method of treating inflammatory ocular disease
US20170107294A1 (en) *	2014-03-21	2017-04-20	Nordlandssykehuset Hf	Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en)	2014-04-16	2015-10-22	Bayer Cropscience Lp	Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en)	2014-04-24	2015-10-29	University Of Oslo	Anti-gluten antibodies and uses thereof
BR112016025470A2 (en)	2014-05-02	2017-08-15	Cerenis Therapeutics Holding S A	therapeutic hdl?
WO2015179654A1 (en)	2014-05-22	2015-11-26	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti b7-h1 antibodies
CN105198999A (en) *	2014-05-27	2015-12-30	上海生物制品研究所有限责任公司	Fusion protein and its preparation method and use
USD763433S1 (en)	2014-06-06	2016-08-09	Anutra Medical, Inc.	Delivery system cassette
USD750768S1 (en)	2014-06-06	2016-03-01	Anutra Medical, Inc.	Fluid administration syringe
USD774182S1 (en)	2014-06-06	2016-12-13	Anutra Medical, Inc.	Anesthetic delivery device
WO2015191781A2 (en)	2014-06-10	2015-12-17	Amgen Inc.	Apelin polypeptides
AU2015276089B2 (en)	2014-06-18	2021-03-18	Csl Behring Gmbh	Therapy using a Factor XII inhibitor in a neurotraumatic disorder
WO2015198199A1 (en)	2014-06-23	2015-12-30	Novartis Ag	Hsa-gdf-15 fusion polypeptide and use thereof.
US9272019B2 (en)	2014-06-24	2016-03-01	Novo Nordisk A/S	MIC-1 fusion proteins and uses thereof
WO2016004113A1 (en)	2014-06-30	2016-01-07	Biogen Ma Inc.	Optimized factor ix gene
US10517875B2 (en)	2014-07-23	2019-12-31	Mayo Foundation for Medical Engineering and Research	Targeting DNA-PKcs and B7-H1 to treat cancer
MD20170020A2 (en)	2014-07-30	2017-07-31	Ngm Biopharmaceuticals, Inc.	Compositions and methods of use for treating metabolic disorders
WO2016020882A2 (en)	2014-08-07	2016-02-11	Novartis Ag	Angiopoetin-like 4 (angptl4) antibodies and methods of use
JO3565B1 (en)	2014-08-07	2020-07-05	Novartis Ag	Angiopoietin-like 4 antibodies and methods of use
US10508137B2 (en) *	2014-08-22	2019-12-17	National Cheng Kung Univeristy	Disintegrin variants and pharmaceutical uses thereof
WO2016044529A1 (en)	2014-09-17	2016-03-24	Bayer Cropscience Lp	Compositions comprising recombinant bacillus cells and another biological control agent
US9616114B1 (en)	2014-09-18	2017-04-11	David Gordon Bermudes	Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CU20170038A7 (en)	2014-09-26	2017-10-05	Bayer Pharma AG	DERIVATIVES OF ADRENOMEDULIN STABILIZED ESPECIALLY USEFUL IN THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR, EDEMATOS AND / OR INFLAMMATORY DISORDERS
MA41044A (en)	2014-10-08	2017-08-15	Novartis Ag	COMPOSITIONS AND METHODS OF USE FOR INCREASED IMMUNE RESPONSE AND CANCER TREATMENT
NZ730563A (en)	2014-10-14	2019-05-31	Halozyme Inc	Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (en)	2014-10-23	2017-08-29	Biogen Ma Inc	ANTI-GPIIB / IIIA ANTIBODIES AND THEIR USES
US20160130324A1 (en) *	2014-10-31	2016-05-12	Shire Human Genetic Therapies, Inc.	C1 Inhibitor Fusion Proteins and Uses Thereof
UA121973C2 (en)	2014-10-31	2020-08-25	Нджм Біофармасьютікалз, Інк.	Compositions and methods of use for treating metabolic disorders
MA40861A (en)	2014-10-31	2017-09-05	Biogen Ma Inc	ANTI-GLYCOPROTEIN IIB / IIIA ANTIBODIES
GB201420139D0 (en)	2014-11-12	2014-12-24	Ucl Business Plc	Factor IX gene therapy
UY36449A (en)	2014-12-19	2016-07-29	Novartis Ag	COMPOSITIONS AND METHODS FOR ANTIBODIES DIRECTED TO BMP6
JP6798993B2 (en) *	2014-12-23	2020-12-09	メルツファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフトアウフアクティーン	Botulinum toxin prefilled container
US10556952B2 (en) *	2015-03-30	2020-02-11	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to Fc gamma receptors
JP2016204292A (en) *	2015-04-21	2016-12-08	国立大学法人熊本大学	Bmp7 mutant-albumin cointegrate, and renal disease therapeutic agent containing the same
HUE046343T2 (en) *	2015-04-29	2020-02-28	Mediolanum Farm S P A	A soluble chimeric interleukin-10 receptor and therapeutic use thereof
WO2016195723A1 (en) *	2015-06-03	2016-12-08	Beller Pharmaceuticals LLC	Methods of treatment for conditions mediated by substance p
CA2982237A1 (en)	2015-06-05	2016-12-08	Novartis Ag	Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
US11752242B2 (en)	2015-06-11	2023-09-12	Ath Therapeutics Inc.	Medical devices, systems, and methods utilizing antithrombin-heparin composition
JOP20200312A1 (en)	2015-06-26	2017-06-16	Novartis Ag	Factor xi antibodies and methods of use
EP3328415B1 (en) *	2015-07-30	2020-11-25	Endor Technologies, S.L.	Colony stimulating factor for use in pancreatic or colon cancer treatment
MX2018001497A (en)	2015-08-03	2018-05-15	Bioverativ Therapeutics Inc	Factor ix fusion proteins and methods of making and using same.
US11236159B2 (en)	2015-08-03	2022-02-01	Novartis Ag	Methods of treating FGF21-associated disorders
JP6978407B2 (en) *	2015-08-06	2021-12-08	ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア	Its use in compositions for treating GLP-1 and metabolic disorders
CA2989966C (en)	2015-08-20	2024-04-30	Albumedix A/S	Albumin variants and conjugates
HUE053937T2 (en)	2015-09-08	2021-08-30	Japan Chem Res	Novel human serum albumin mutant
JP6516925B2 (en)	2015-09-09	2019-05-22	ノバルティスアーゲー	Thymic stromal lymphopoietic factor (TSLP) binding antibodies and methods of using the antibodies
AU2016320748B2 (en)	2015-09-09	2019-05-02	Novartis Ag	Thymic stromal lymphopoietin (TSLP)-binding antibodies and methods of using the antibodies
EP3347056A4 (en)	2015-09-11	2019-02-27	The Board of Trustees of the Leland Stanford Junior University	Biologically relevant orthogonal cytokine/receptor pairs
US10875923B2 (en)	2015-10-30	2020-12-29	Mayo Foundation For Medical Education And Research	Antibodies to B7-H1
EA201891331A1 (en)	2015-12-04	2018-12-28	Бёрингер Ингельхайм Интернациональ Гмбх	BIPARATOPE POLYPEPTIDES - ANTAGONISTS OF TRANSMISSION OF WNT SIGNAL IN TUMOR CELLS
CO2018007151A2 (en)	2015-12-11	2018-09-20	Dyax Corp	Plasma kallikrein inhibitors and their uses to treat hereditary angioedema attack
CA3008102A1 (en)	2015-12-18	2017-06-22	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
US20190000923A1 (en)	2015-12-22	2019-01-03	Novartis Ag	Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP3402819A1 (en)	2016-01-11	2018-11-21	Novartis AG	Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
EP3405492B1 (en)	2016-01-21	2020-10-21	Novartis AG	Multispecific molecules targeting cll-1
AU2017214378B2 (en)	2016-02-01	2023-05-04	Bioverativ Therapeutics Inc.	Optimized Factor VIII genes
WO2017159540A1 (en) *	2016-03-14	2017-09-21	Ｊｃｒファーマ株式会社	Serum albumin-20 k growth hormone fusion protein
KR20220004226A (en)	2016-03-22	2022-01-11	바이오노믹스 리미티드	Administration of an anti-lgr5 monoclonal antibody
TWI815793B (en)	2016-03-31	2023-09-21	美商恩格姆生物製藥公司	Binding proteins and methods of use thereof
CA3019851A1 (en)	2016-04-06	2017-10-12	Csl Limited	Method of treating atherosclerosis
WO2017189724A1 (en)	2016-04-27	2017-11-02	Novartis Ag	Antibodies against growth differentiation factor 15 and uses thereof
MY193112A (en)	2016-05-18	2022-09-26	Boehringer Ingelheim Int	Anti pd-1 and anti-lag3 antibodies for cancer treatment
KR102433503B1 (en)	2016-05-24	2022-08-18	노보 노르디스크 에이/에스	MIC-1 compounds and their use
WO2017216724A1 (en)	2016-06-15	2017-12-21	Novartis Ag	Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
AU2017294555B2 (en) *	2016-07-08	2022-04-28	CSL Behring Lengnau AG	Subcutaneous administration of long-acting factor IX in humans
WO2018014260A1 (en)	2016-07-20	2018-01-25	Nanjing Legend Biotech Co., Ltd.	Multispecific antigen binding proteins and methods of use thereof
US20190175683A1 (en)	2016-08-05	2019-06-13	Csl Behring Gmbh	Pharmaceutical formulations of c1 esterase inhibitor
AU2017316513A1 (en)	2016-08-23	2019-03-28	Csl Behring Gmbh	Method of preventing acute attacks of hereditary angioedema associated with C1 esterase inhibitor deficiency
WO2018068201A1 (en)	2016-10-11	2018-04-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies and variants thereof against ctla-4
US20210333279A1 (en)	2016-11-04	2021-10-28	Aarhus Universitet	Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
AU2017360043A1 (en) *	2016-11-18	2019-06-20	Hospital Clinic De Barcelona	Combined CD6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
WO2018102760A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of inducing immune tolerance to clotting factors
WO2018102743A1 (en)	2016-12-02	2018-06-07	Bioverativ Therapeutics Inc.	Methods of treating hemophilic arthropathy using chimeric clotting factors
US11180535B1 (en)	2016-12-07	2021-11-23	David Gordon Bermudes	Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en)	2016-12-07	2021-09-28	David Gordon Bermudes	Chimeric protein toxins for expression by therapeutic bacteria
US20200031895A1 (en)	2016-12-16	2020-01-30	Biogen Ma Inc.	Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en)	2017-02-14	2018-08-15	Boehringer Ingelheim International GmbH	Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
CA3048156A1 (en)	2016-12-23	2018-06-28	Novartis Ag	Factor xi antibodies and methods of use
AU2017383537B2 (en)	2016-12-23	2024-10-03	Novartis Ag	Methods of treatment with anti-Factor XI/XIa antibodies
AU2017382323B2 (en)	2016-12-23	2024-06-13	President And Fellows Of Harvard College	Gene editing of PCSK9
WO2018132768A1 (en)	2017-01-13	2018-07-19	Sanna Pietro P	Methods and compositions for treating hpa hyperactivity
CR20190389A (en)	2017-01-31	2019-11-26	Bioverativ Therapeutics Inc	Factor ix fusion proteins and methods of making and using same
BR112019016344A2 (en)	2017-02-08	2020-04-07	Novartis Ag	mimetic antibodies fgf21 and uses thereof
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
US20200131225A1 (en)	2017-04-20	2020-04-30	Novo Nordisk A/S	Methods of purification of albumin fusion proteins
TWI710377B (en)	2017-05-23	2020-11-21	丹麥商諾佛儂迪克股份有限公司	Mic-1 compounds and uses thereof
EA201992765A1 (en)	2017-05-24	2020-03-25	Новартис Аг	PROTEINS BASED ON ANTIBODIES WITH VACCINATED CYTOKINE AND METHODS OF THEIR APPLICATION IN TREATMENT OF CANCER
PE20200610A1 (en)	2017-05-31	2020-03-10	Boehringer Ingelheim Int	POLYPEPTIDES THAT ANTAGONIZE WNT SIGNALING IN TUMOR CELLS
WO2018229715A1 (en)	2017-06-16	2018-12-20	Novartis Ag	Compositions comprising anti-cd32b antibodies and methods of use thereof
EP3638296A1 (en)	2017-06-16	2020-04-22	The University Of Chicago	Compositions and methods for inducing immune tolerance
WO2019002532A1 (en)	2017-06-29	2019-01-03	CSL Behring Lengnau AG	21-day dosing regimen for fusion proteins comprising factor ix and human albumin for prophylactic treatment of hemophilia and methods thereof
LT3661562T (en)	2017-08-04	2024-10-25	Amgen Inc.	Method of conjugation of cys-mabs
WO2019032898A1 (en)	2017-08-09	2019-02-14	Bioverativ Therapeutics Inc.	Nucleic acid molecules and uses thereof
WO2019036605A2 (en)	2017-08-17	2019-02-21	Massachusetts Institute Of Technology	Multiple specificity binders of cxc chemokines and uses thereof
US12059456B2 (en)	2017-09-15	2024-08-13	Cedars-Sinai Medical Center	Methods of using C1 esterase inhibitor for improving early onset and long-term function of kidney transplants from grafts associated with delayed graft function
JP2020537668A (en)	2017-10-18	2020-12-24	シーエスエルリミティド	Human serum albumin mutant and its use
US20210040205A1 (en)	2017-10-25	2021-02-11	Novartis Ag	Antibodies targeting cd32b and methods of use thereof
EP3723804A4 (en)	2017-12-15	2021-10-20	CSL Limited	Use of a fxiia-inhibitor in the treatment of renal fibrosis and/or chronic kidney disease
WO2019129054A1 (en)	2017-12-27	2019-07-04	信达生物制药(苏州)有限公司	Triabody, preparation method and use thereof
CN111699198B (en)	2017-12-28	2023-09-05	南京传奇生物科技有限公司	Single domain antibodies to TIGIT and variants thereof
US11246908B2 (en) *	2018-01-10	2022-02-15	The Johns Hopkins University	Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
CN111699200B (en)	2018-01-15	2023-05-26	南京传奇生物科技有限公司	Single domain antibodies and variants thereof against PD-1
CN111918674A (en)	2018-02-01	2020-11-10	比奥维拉迪维治疗股份有限公司	Use of lentiviral vectors expressing factor VIII
HRP20230984T1 (en) *	2018-03-13	2023-12-08	Sepsia Therapeutics, S.L.	Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
US20210260210A1 (en)	2018-03-13	2021-08-26	Zymeworks Inc.	Anti-her2 biparatopic antibody-drug conjugates and methods of use
EA202092316A1 (en)	2018-03-28	2021-05-25	Бристол-Маерс Сквибб Компани	FUSION PROTEINS OF INTERLEUKIN-2 / ALPHA-RECEPTOR OF INTERLEUKIN-2 AND METHODS OF APPLICATION
EP3774917A4 (en)	2018-03-30	2022-01-19	Nanjing Legend Biotech Co., Ltd.	Single-domain antibodies against lag-3 and uses thereof
KR102119197B1 (en) *	2018-04-23	2020-06-05	주식회사 엘베이스	Composition for autophagy inhibiting in cell, And pharmaceutical composition for preventing or treating tumor disease, or inhibiting anti-cancer agents resistance containing the same
SG11202011308VA (en)	2018-05-14	2020-12-30	Werewolf Therapeutics Inc	Activatable cytokine polypeptides and methods of use thereof
BR112020023160A2 (en)	2018-05-14	2021-02-02	Werewolf Therapeutics, Inc.	activable interleukin 2 polypeptides and methods of using these
CN112512555A (en)	2018-05-18	2021-03-16	比奥维拉迪维治疗股份有限公司	Methods of treating hemophilia A
EP3569618A1 (en)	2018-05-19	2019-11-20	Boehringer Ingelheim International GmbH	Antagonizing cd73 antibody
TW202015726A (en)	2018-05-30	2020-05-01	瑞士商諾華公司	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CR20200571A (en)	2018-06-01	2021-01-18	Novartis Ag	Binding molecules against bcma and uses thereof
WO2019246003A1 (en)	2018-06-18	2019-12-26	Anwita Biosciences, Inc.	Anti-mesothelin constructs and uses thereof
JP7492463B2 (en)	2018-07-03	2024-05-29	ブリストル－マイヤーズスクイブカンパニー	FGF-21 preparation
SG11202101157VA (en)	2018-08-09	2021-03-30	Bioverativ Therapeutics Inc	Nucleic acid molecules and uses thereof for non-viral gene therapy
US10842885B2 (en)	2018-08-20	2020-11-24	Ucl Business Ltd	Factor IX encoding nucleotides
US11590223B2 (en)	2018-08-31	2023-02-28	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for therapeutic antibodies
WO2020058759A1 (en) *	2018-09-17	2020-03-26	Kyoto University	Administration of an anti-c5 agent for treatment of hepatic injury or failure
CN113286812A (en)	2018-09-27	2021-08-20	西里欧发展公司	Masked cytokine polypeptides
UY38407A (en)	2018-10-15	2020-05-29	Novartis Ag	TREM2 STABILIZING ANTIBODIES
BR112021008200A2 (en) *	2018-10-29	2021-12-14	Spin Therapeutics Llc	Compositions and methods for alpha-1-antitrypsin disorders
GB201818477D0 (en)	2018-11-13	2018-12-26	Emstopa Ltd	Tissue plasminogen activator antibodies and method of use thereof
WO2020109978A1 (en)	2018-11-26	2020-06-04	Novartis Ag	Lpl-gpihbp1 fusion polypeptides
BR112021010047A2 (en)	2018-12-06	2021-08-24	Bioverativ Therapeutics Inc.	Use of lentiviral vectors expressing factor ix
WO2020198075A2 (en)	2019-03-22	2020-10-01	Reflexion Pharmaceuticals, Inc.	Multivalent d-peptidic compounds for target proteins
JP2022521353A (en)	2019-03-22	2022-04-06	リフレクションファーマシューティカルズ，インコーポレイテッド	D-Peptidic Compounds for VEGF
US20220169706A1 (en)	2019-03-28	2022-06-02	Danisco Us Inc	Engineered antibodies
CN114026085A (en)	2019-04-11	2022-02-08	安吉昂生物医药公司	(E) Solid forms of (E) -3- [2- (2-thienyl) vinyl ] -1H-pyrazole
CA3137512A1 (en)	2019-05-14	2020-11-19	Werewolf Therapeutics, Inc.	Separation moieties and methods and use thereof
WO2020236797A1 (en)	2019-05-21	2020-11-26	Novartis Ag	Variant cd58 domains and uses thereof
EP3972998A1 (en)	2019-05-21	2022-03-30	Novartis AG	Cd19 binding molecules and uses thereof
JP2022532928A (en)	2019-05-24	2022-07-20	サノフイ	Methods for treating systemic scleroderma
CA3143584A1 (en)	2019-06-18	2020-12-24	Bayer Aktiengesellschaft	Adrenomedullin-analogues for long-term stabilization and their use
BR112022003762A2 (en)	2019-09-06	2022-05-31	Novartis Ag	Therapeutic fusion proteins
JP2022548881A (en)	2019-09-18	2022-11-22	ノバルティスアーゲー	ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy
TW202124446A (en)	2019-09-18	2021-07-01	瑞士商諾華公司	Combination therapies with entpd2 antibodies
CA3152600A1 (en)	2019-09-30	2021-04-08	Andrew KROETSCH	Lentiviral vector formulations
KR20220083784A (en)	2019-10-17	2022-06-20	제이씨알 파마 가부시키가이샤	Method for producing a fusion protein of serum albumin and growth hormone
CN114728043B (en)	2019-10-30	2024-04-16	Jcr制药股份有限公司	Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
CA3155981A1 (en)	2019-11-14	2021-05-20	William Winston	Activatable cytokine polypeptides and methods of use thereof
EP4069200A1 (en)	2019-12-04	2022-10-12	Albumedix Ltd	Methods and compositions produced thereby
AU2020401371A1 (en)	2019-12-13	2022-07-21	Synthekine, Inc.	IL-2 orthologs and methods of use
US20210181200A1 (en) *	2019-12-17	2021-06-17	Women's College Hospital	Ovarian cancer biomarker and methods of using same
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
BR112022020428A2 (en)	2020-04-09	2023-03-07	Verve Therapeutics Inc	BASE EDITION OF ANGPTL3 AND METHODS OF USE FOR THE TREATMENT OF DISEASES
BR112022021447A2 (en)	2020-05-19	2022-12-13	Boehringer Ingelheim Int	BINDING MOLECULES FOR THE TREATMENT OF CANCER
CA3182800A1 (en)	2020-06-14	2021-12-23	Vertex Pharmaceuticals Inc.	Complement factor i-related compositions and methods
CN117043186A (en)	2020-10-21	2023-11-10	勃林格殷格翰国际有限公司	Agonistic TrkB binding molecules for the treatment of ocular diseases
IL302507A (en) *	2020-10-30	2023-06-01	Shenzhen Protgen Ltd	Use of human serum albumin in treatment of diseases
CA3199095A1 (en)	2020-11-06	2022-05-12	Novartis Ag	Cd19 binding molecules and uses thereof
CN114478800B (en) *	2021-02-05	2022-10-11	华南理工大学	Fusion protein based on serum albumin, nano assembly, preparation method and application thereof
IL305301A (en)	2021-02-19	2023-10-01	Us Health	SINGLE DOMAIN ANTIBODIES THAT NEUTRALIZE SARS-CoV-2
EP4355778A1 (en)	2021-06-17	2024-04-24	Boehringer Ingelheim International GmbH	Novel tri-specific binding molecules
MX2024000233A (en) *	2021-06-21	2024-03-14	Juvena Therapeutics Inc	Regenerative polypeptides and uses thereof.
CN114133458B (en) *	2021-12-08	2023-11-14	福州大学	Method for fusing polypeptide in human serum albumin
WO2023209568A1 (en)	2022-04-26	2023-11-02	Novartis Ag	Multispecific antibodies targeting il-13 and il-18
WO2024015953A1 (en)	2022-07-15	2024-01-18	Danisco Us Inc.	Methods for producing monoclonal antibodies
US20240052065A1 (en)	2022-07-15	2024-02-15	Boehringer Ingelheim International Gmbh	Binding molecules for the treatment of cancer
WO2024083843A1 (en)	2022-10-18	2024-04-25	Confo Therapeutics N.V.	Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024130158A1 (en)	2022-12-16	2024-06-20	Modernatx, Inc.	Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
WO2024130304A1 (en) *	2022-12-20	2024-06-27	CSL Innovation Pty Ltd	Fcrn antagonists and uses thereof
EP4389762A1 (en)	2022-12-23	2024-06-26	Ospedale San Raffaele S.r.l.	Inhibitors of dux4 activity and their use in therapy.
WO2024178305A1 (en)	2023-02-24	2024-08-29	Modernatx, Inc.	Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
EP4442251A1 (en)	2023-04-05	2024-10-09	Albumedix Ltd	Formulations and uses thereof

Family Cites Families (517)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5625041A (en) *	1990-09-12	1997-04-29	Delta Biotechnology Limited	Purification of proteins
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
DE2449885C3 (en)	1974-10-21	1980-04-30	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Process for the production of chemically modified, long-life hemoglobin preparations as well as the modified hemoglobin preparation produced by this process
US4002531A (en)	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4363877B1 (en)	1977-09-23	1998-05-26	Univ California	Recombinant dna transfer vectors
US4264731A (en) *	1977-05-27	1981-04-28	The Regents Of The University Of California	DNA Joining method
US4440859A (en) *	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4283489A (en)	1977-09-23	1981-08-11	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en)	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en)	1977-11-08	1982-12-28	Genentech, Inc.	Method for microbial polypeptide expression
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4447538A (en) *	1978-04-19	1984-05-08	Regents Of The University Of California	Microorganism containing gene for human chorionic somatomammotropin
US4652525A (en) *	1978-04-19	1987-03-24	The Regents Of The University Of California	Recombinant bacterial plasmids containing the coding sequences of insulin genes
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US5514567A (en) *	1979-01-30	1996-05-07	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
US4342832A (en)	1979-07-05	1982-08-03	Genentech, Inc.	Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en)	1979-10-30	1984-08-23	Juridical Foundation, Japanese Foundation For Cancer Research	Human interferon dna
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
EP0032134B2 (en)	1980-01-08	1993-10-13	Biogen, Inc.	Dna sequences, recombinant dna molecules and processes for producing human interferon-alpha like polypeptides
DK170476B1 (en)	1980-04-03	1995-09-11	Biogen Inc	Recombinant DNA molecule, uni-cellular host transformed with at least one recombinant DNA molecule, method for transforming a unicellular host, and methods for producing a polypeptide exhibiting the immunological or biological activity of human beta-interferon
DE3023787A1 (en)	1980-06-25	1982-01-21	Studiengesellschaft Kohle mbH, 4330 Mülheim	METHOD FOR INCREASING THE INCORPORATION AND EXPRESSION OF GENETIC MATERIAL IN THE CORE OF INTACT CELLS BY LIPOSOME
US6610830B1 (en)	1980-07-01	2003-08-26	Hoffman-La Roche Inc.	Microbial production of mature human leukocyte interferons
NZ198445A (en)	1980-09-25	1984-05-31	Genentech Inc	Production of human fibroblast interferon by recombinant dna technology
US4456748A (en)	1981-02-23	1984-06-26	Genentech, Inc.	Hybrid human leukocyte interferons
EP0052322B1 (en)	1980-11-10	1985-03-27	Gersonde, Klaus, Prof. Dr.	Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
DE3273787D1 (en)	1981-02-04	1986-11-20	Japan Found Cancer	Human interferon-beta gene
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
NZ199722A (en) *	1981-02-25	1985-12-13	Genentech Inc	Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en)	1981-03-11	1982-09-14	Ajinomoto Co Inc	Novel erythropoietin and its preparation
US4873191A (en)	1981-06-12	1989-10-10	Ohio University	Genetic transformation of zygotes
US4792602A (en)	1981-06-19	1988-12-20	Cornell Research Foundation, Inc.	Adaptors, and synthesis and cloning of proinsulin genes
US4474893A (en)	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
US4714681A (en)	1981-07-01	1987-12-22	The Board Of Reagents, The University Of Texas System Cancer Center	Quadroma cells and trioma cells and methods for the production of same
US4485045A (en)	1981-07-06	1984-11-27	Research Corporation	Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en)	1981-08-28	1985-09-29	Genentech Inc	Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en)	1981-10-19	1987-05-07	Genentech Inc.	Human immune interferon by recombinant dna
EP0079739A3 (en)	1981-11-12	1984-08-08	The Upjohn Company	Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en)	1981-12-14	1984-07-25	The President And Fellows Of Harvard College	Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58118008A (en)	1982-01-06	1983-07-13	Nec Corp	Data processor
IT1167610B (en)	1982-01-19	1987-05-13	Cetus Corp	MULTICLASS HYBRID INTERFRERON, PHARMACEUTICAL COMPOSITION CONTAINING IT AND PRODUCTION PROCESS
EP0088046B1 (en)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipids in the aqueous phase
US4450103A (en) *	1982-03-01	1984-05-22	Cetus Corporation	Process for recovering human IFN-β from a transformed microorganism
US4775622A (en)	1982-03-08	1988-10-04	Genentech, Inc.	Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) *	1982-03-22	1987-06-02	Genentech, Inc.	DNA vectors encoding a novel human growth hormone-variant protein
US4925919A (en) *	1984-04-25	1990-05-15	Roland Mertelsmann	Purified interleukin 2
US4778879A (en)	1982-04-20	1988-10-18	Sloan-Kettering Institute For Cancer Research	Highly purified human interleukin 2 and method
US4499188A (en) *	1982-05-05	1985-02-12	Cetus Corporation	Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en)	1982-05-06	2005-08-30	Intermune, Inc.	Manufacture and expression of large structural genes
DE3218121A1 (en)	1982-05-14	1983-11-17	Leskovar, Peter, Dr.-Ing., 8000 München	Pharmaceutical compositions for tumour treatment
EP0102324A3 (en)	1982-07-29	1984-11-07	Ciba-Geigy Ag	Lipids and surfactants in an aqueous medium
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4992271A (en)	1982-09-23	1991-02-12	Cetus Corporation	Formulation for lipophilic IL-2 proteins
US4462940A (en) *	1982-09-23	1984-07-31	Cetus Corporation	Process for the recovery of human β-interferon-like polypeptides
IE56026B1 (en)	1982-10-19	1991-03-27	Cetus Corp	Cysteine-depleted muteins of biologically active proteins
US4588585A (en)	1982-10-19	1986-05-13	Cetus Corporation	Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) *	1982-11-01	1990-10-30	Cetus Corporation	Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en)	1982-11-16	1988-05-03	Cytogen Corporation	Antibody-metal ion complexes
DE3382547D1 (en)	1983-01-12	1992-05-27	Chiron Corp	SECRETORIC EXPRESSION IN EUKARYOTS.
US4840934A (en) *	1983-01-25	1989-06-20	Eleanor Roosevelt Institute For Cancer Research, Inc.	Therapeutic method using T cell growth factor
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5015575A (en) *	1983-04-07	1991-05-14	Chiron Corporation	Hybrid DNA synthesis of insulin
US4914026A (en) *	1983-04-07	1990-04-03	Chiron Corporation	Alpha factor leader sequence directed secretion of insulin
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4518584A (en)	1983-04-15	1985-05-21	Cetus Corporation	Human recombinant interleukin-2 muteins
WO1984004330A1 (en)	1983-04-22	1984-11-08	Amgen	Secretion of exogenous polypeptides from yeast
NZ207926A (en)	1983-04-25	1988-04-29	Genentech Inc	Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) *	1983-04-25	1991-04-23	Genentech, Inc.	Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) *	1983-06-08	1985-11-19	Mattheus F.A. Goosen	Slow release injectable insulin composition
US4544545A (en)	1983-06-20	1985-10-01	Trustees University Of Massachusetts	Liposomes containing modified cholesterol for organ targeting
US4576813A (en)	1983-07-05	1986-03-18	Monsanto Company	Heat recovery from concentrated sulfuric acid
HUT35524A (en)	1983-08-02	1985-07-29	Hoechst Ag	Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (en)	1983-09-23	1985-05-17	ジェネックス・コーポレイション	Variant control region
ATE159858T1 (en)	1983-09-26	1997-11-15	Ehrenfeld Udo	AGENT AND PRODUCT FOR THE DIAGNOSIS AND THERAPY OF TUMORS AND FOR THE TREATMENT OF WEAKNESSES OF THE CELLULAR AND HUMORAL IMMUNE DEFENSE
US4518564A (en) *	1983-10-03	1985-05-21	Jeneric Industries, Inc.	Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
GB8334102D0 (en)	1983-12-21	1984-02-01	Searle & Co	Interferons with cysteine pattern
NZ210501A (en) *	1983-12-13	1991-08-27	Kirin Amgen Inc	Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en)	1983-12-13	1987-10-27	Kiren-Amgen, Inc.	DNA sequences encoding erythropoietin
US4855238A (en)	1983-12-16	1989-08-08	Genentech, Inc.	Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en)	1983-12-22	1984-02-01	Bass Plc	Fermentation processes
JPS60136596A (en)	1983-12-26	1985-07-20	Suntory Ltd	Peptide and diuretic comprising it as active ingredient
US4908434A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Process for preparing purified interleukin-2
US4908433A (en) *	1984-04-25	1990-03-13	Sloan-Kettering Institute For Cancer Research	Uses of interleukin-2
CA1213537A (en)	1984-05-01	1986-11-04	Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee	Polypeptide expression method
FR2564106B1 (en) *	1984-05-09	1988-04-22	Transgene Sa	FACTOR IX EXPRESSION VECTORS, CELLS TRANSFORMED BY THESE VECTORS, AND PROCESS FOR THE PREPARATION OF FACTOR IX.
DK58285D0 (en) *	1984-05-30	1985-02-08	Novo Industri As	PEPTIDES AND MANUFACTURING AND USING THEREOF
EP0172619A1 (en)	1984-06-20	1986-02-26	Takeda Chemical Industries, Ltd.	Novel transformant and use thereof
US4736866A (en)	1984-06-22	1988-04-12	President And Fellows Of Harvard College	Transgenic non-human mammals
US5908763A (en)	1984-07-06	1999-06-01	Novartis Corporation	DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS6147500A (en)	1984-08-15	1986-03-07	Res Dev Corp Of Japan	Chimera monoclonal antibody and its preparation
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (en)	1984-08-27	1987-11-25	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptors by dna splicing and expression
US4716217A (en)	1984-08-31	1987-12-29	University Patents, Inc.	Hybrid lymphoblastoid-leukocyte human interferons
US4734491A (en)	1984-08-31	1988-03-29	University Patents, Inc.	DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
US4959314A (en)	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US5049386A (en)	1985-01-07	1991-09-17	Syntex (U.S.A.) Inc.	N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en)	1985-01-07	1990-01-30	Syntex (U.S.A.) Inc.	N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4970300A (en) *	1985-02-01	1990-11-13	New York University	Modified factor VIII
GB8504099D0 (en) *	1985-02-18	1985-03-20	Wellcome Found	Physiologically active substances
FR2579224B1 (en) *	1985-03-25	1987-05-22	Genetica	PROCESS FOR THE MICROBIOLOGICAL PREPARATION OF HUMAN SERUM-ALBUMIN
CA1260858A (en)	1985-03-28	1989-09-26	Lawrence S. Cousens	Expression using fused genes providing for protein product
US4751180A (en) *	1985-03-28	1988-06-14	Chiron Corporation	Expression using fused genes providing for protein product
CA1319120C (en)	1985-04-01	1993-06-15	John Henry Kenten	Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GR860984B (en)	1985-04-17	1986-08-18	Zymogenetics Inc	Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en)	1985-04-22	1985-05-30	Bass Plc	Isolation of fermentation products
EP0206733A1 (en)	1985-06-17	1986-12-30	Genex Corporation	Cloned human serum albumin gene
US4980286A (en)	1985-07-05	1990-12-25	Whitehead Institute For Biomedical Research	In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en)	1985-08-23	1989-03-07	Kirin- Amgen Inc.	Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
JPS6296086A (en)	1985-10-21	1987-05-02	Agency Of Ind Science & Technol	Composite plasmid
US5139941A (en)	1985-10-31	1992-08-18	University Of Florida Research Foundation, Inc.	AAV transduction vectors
US5576195A (en)	1985-11-01	1996-11-19	Xoma Corporation	Vectors with pectate lyase signal sequence
AU606320B2 (en)	1985-11-01	1991-02-07	International Genetic Engineering, Inc.	Modular assembly of antibody genes, antibodies prepared thereby and use
US5641663A (en)	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
CA1295566C (en)	1987-07-21	1992-02-11	Robert T. Garvin	Characterization and structure of genes for protease a and protease b from streptomyces griseus
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
FR2594846B1 (en)	1986-02-21	1989-10-20	Genetica	PROCESS FOR THE PREPARATION OF MATURE HUMAN ALBUMIN SERUM
EP0237019A3 (en)	1986-03-14	1988-03-09	Toray Industries, Inc.	Interferon conjugate and production thereof using recombinant gene
IT1203758B (en)	1986-03-27	1989-02-23	Univ Roma	CLONING AND EXPRESSION VECTORS OF HETEROLOGICAL GENES IN YEASTS AND YEASES TRANSFORMED WITH SUCH CARRIERS
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DK179286D0 (en)	1986-04-18	1986-04-18	Nordisk Gentofte	INSULIN PREPARATION
US4765980A (en)	1986-04-28	1988-08-23	International Minerals & Chemical Corp.	Stabilized porcine growth hormone
US4859609A (en)	1986-04-30	1989-08-22	Genentech, Inc.	Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) *	1986-05-27	1991-07-02	Schering Corporation	Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
IT1204400B (en) *	1986-06-20	1989-03-01	Sclavo Spa	PHARMACEUTICAL COMPOSITIONS CONTAINING A CALCITONIN
GB8615701D0 (en)	1986-06-27	1986-08-06	Delta Biotechnology Ltd	Stable gene integration vector
IT1196484B (en)	1986-07-11	1988-11-16	Sclavo Spa	YEAST EXPRESSION AND SECRETION VECTOR, USEFUL FOR THE PREPARATION OF HETEROLOGICAL PROTEINS
GR871067B (en)	1986-07-18	1987-11-19	Chugai Pharmaceutical Co Ltd	Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en)	1986-07-23	1989-08-15	Phillips Petroleum Company	Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en)	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) *	1986-08-12	1991-03-26	Schering Corporation	Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) *	1986-08-29	1986-10-08	Delta Biotechnology Ltd	Yeast promoter
US4946778A (en)	1987-09-21	1990-08-07	Genex Corporation	Single polypeptide chain binding molecules
US4929442A (en) *	1986-09-26	1990-05-29	Exovir, Inc.	Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) *	1986-11-21	1996-04-16	Cetus Oncology Corporation	Method for treating biological damage using a free-radial scavenger and interleukin-2
WO1988007057A1 (en)	1987-03-13	1988-09-22	Amgen Inc.	Purified platelet-derived growth factor and methods for purification thereof
US4835260A (en) *	1987-03-20	1989-05-30	Genetics Institute, Inc.	Erythropoietin composition
AU613030B2 (en) *	1987-04-09	1991-07-25	Novozymes Delta Limited	Yeast vector
JPH0198489A (en)	1987-04-22	1989-04-17	Chiron Corp	Recombinant production of platelet-derived growth factor a chain polypeptide
US5258498A (en)	1987-05-21	1993-11-02	Creative Biomolecules, Inc.	Polypeptide linkers for production of biosynthetic proteins
US4994560A (en)	1987-06-24	1991-02-19	The Dow Chemical Company	Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en)	1987-06-24	1996-02-06	The Dow Chemical Company	Functionalized polyamine chelants
GB8717430D0 (en)	1987-07-23	1987-08-26	Celltech Ltd	Recombinant dna product
HU208553B (en)	1987-07-28	1993-11-29	Gist Brocades Nv	Process for producing polypeptides, plasmides coding them and transformed kluyveromyces
JP2627899B2 (en)	1987-08-19	1997-07-09	株式会社ビタミン研究所	Production method of gene-encapsulated liposome
SE459586B (en)	1987-09-14	1989-07-17	Mta Szegedi Biolog Koezponti	THE STRUCTURES CODING FOR AUTHENTIC HUMAN SERUM ALBUMIN AND PROCEDURES FOR ITS PREPARATION
PT88641B (en)	1987-10-02	1993-04-30	Genentech Inc	METHOD FOR PREPARING A VARIETY OF ADHESION
US5336603A (en)	1987-10-02	1994-08-09	Genentech, Inc.	CD4 adheson variants
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
JPH0811074B2 (en)	1987-10-30	1996-02-07	財団法人化学及血清療法研究所	Recombinant plasmid incorporating a gene encoding prealbumin and method for producing prealbumin using the same
JP2791418B2 (en) *	1987-12-02	1998-08-27	株式会社ミドリ十字	Method for producing heterologous protein, recombinant DNA, transformant
ZA89430B (en)	1988-01-22	1989-10-25	Gen Hospital Corp	Cloned genes encoding ig-cd4 fusion proteins and the use thereof
JPH01240191A (en) *	1988-02-16	1989-09-25	Green Cross Corp:The	Novel signal peptide functioning by yeast and secretory manifestation of foreign protein using same
JPH01215289A (en)	1988-02-22	1989-08-29	Toa Nenryo Kogyo Kk	Production of normal human serum albumin a through gene recombination
US5066489A (en)	1988-03-28	1991-11-19	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US4999339A (en) *	1988-03-28	1991-03-12	Cetus Corporation	Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5763394A (en) *	1988-04-15	1998-06-09	Genentech, Inc.	Human growth hormone aqueous formulation
US5061488A (en)	1988-04-15	1991-10-29	The United States Of America As Represented Department Of Health & Human Services	Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096707A (en) *	1988-04-15	1992-03-17	The United States Of America As Represented By The Department Of Health And Human Services	Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
US5096885A (en) *	1988-04-15	1992-03-17	Genentech, Inc.	Human growth hormone formulation
GB8809129D0 (en)	1988-04-18	1988-05-18	Celltech Ltd	Recombinant dna methods vectors and host cells
IL89992A0 (en)	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
US5126129A (en) *	1988-05-23	1992-06-30	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services	Cancer therapy using interleukin-2 and flavone compounds
CN1033030C (en)	1988-06-24	1996-10-16	唐化学原料公司	Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
US5756065A (en)	1988-06-24	1998-05-26	The Dow Chemical Company	Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
JP2831073B2 (en)	1988-06-24	1998-12-02	ザダウケミカルカンパニー	Macrocyclic bifunctional chelating agents, their complexes and their antibody conjugates
US5274119A (en)	1988-07-01	1993-12-28	The Dow Chemical Company	Vicinal diols
KR100195632B1 (en)	1988-07-23	1999-06-15	스티븐 조지 가랜드	New secretory leader sequences
US4925648A (en)	1988-07-29	1990-05-15	Immunomedics, Inc.	Detection and treatment of infectious and inflammatory lesions
FR2649991B2 (en)	1988-08-05	1994-03-04	Rhone Poulenc Sante	USE OF STABLE DERIVATIVES OF PLASMID PKD1 FOR THE EXPRESSION AND SECRETION OF HETEROLOGOUS PROTEINS IN YEASTS OF THE GENUS KLUYVEROMYCES
FR2635115B1 (en)	1988-08-05	1992-04-03	Rhone Poulenc Sante	PROCESS FOR THE PREPARATION OF HUMAN ALBUMIN SERUM FROM YEAST
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
CA1340288C (en)	1988-09-02	1998-12-29	Robert Charles Ladner	Generation and selection of novel binding proteins
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5260202A (en)	1988-09-07	1993-11-09	Delta Biotechnology Limited	Fermentation method
JPH02227079A (en)	1988-10-06	1990-09-10	Tonen Corp	Human serum albumin fragment
US5349052A (en)	1988-10-20	1994-09-20	Royal Free Hospital School Of Medicine	Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en)	1988-10-20	1994-03-29	Denki Kagaku Kogyo Kabushiki Kaisha	Colony stimulating factor-gelatin conjugate
JPH02117384A (en)	1988-10-26	1990-05-01	Tonen Corp	Production of human serum albumin a by yeast host
US5759802A (en)	1988-10-26	1998-06-02	Tonen Corporation	Production of human serum alubumin A
US5342604A (en)	1988-10-31	1994-08-30	The Dow Chemical Company	Complexes possessing ortho ligating functionality
US5696239A (en)	1988-10-31	1997-12-09	The Dow Chemical Company	Conjugates possessing ortho ligating functionality and complexes thereof
US5256410A (en)	1988-12-01	1993-10-26	Schering Corporation	Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en)	1988-12-19	1990-12-04	Vipont Pharmaceutical, Inc.	Muscosal delivery systems for treatment of periodontal disease
CA2006596C (en)	1988-12-22	2000-09-05	Rika Ishikawa	Chemically-modified g-csf
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
DK105489D0 (en) *	1989-03-03	1989-03-03	Novo Nordisk As	POLYPEPTIDE
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5116964A (en) *	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5705363A (en) *	1989-03-02	1998-01-06	The Women's Research Institute	Recombinant production of human interferon τ polypeptides and nucleic acids
US5693622A (en)	1989-03-21	1997-12-02	Vical Incorporated	Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
JP3250802B2 (en)	1989-03-21	2002-01-28	バイカル・インコーポレイテッド	Expression of exogenous polynucleotide sequences in vertebrates
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
US5231020A (en)	1989-03-30	1993-07-27	Dna Plant Technology Corporation	Genetic engineering of novel plant phenotypes
US5328470A (en)	1989-03-31	1994-07-12	The Regents Of The University Of Michigan	Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DK0392300T3 (en) *	1989-04-11	1992-09-28	Boehringer Ingelheim Int	Use of drugs containing at least one cytokine for the systemic treatment of pre-neoplastic lesions
EP0395918A3 (en)	1989-04-13	1991-10-23	Vascular Laboratory, Inc.	Plasminogen activator complex of pure pro-urokinase covalently bound by a disulfide bridge to human serum albumin
US5324844A (en)	1989-04-19	1994-06-28	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en)	1989-04-26	1990-10-31	F. Hoffmann-La Roche Ag	Chimaeric CD4-immunoglobulin polypeptides
GB8909916D0 (en) *	1989-04-29	1989-06-14	Delta Biotechnology Ltd	Polypeptides
ATE92107T1 (en)	1989-04-29	1993-08-15	Delta Biotechnology Ltd	N-TERMINAL FRAGMENTS OF HUMAN SERUM ALBUMIN-CONTAINING FUSION PROTEINS.
US5766883A (en) *	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
US5332671A (en)	1989-05-12	1994-07-26	Genetech, Inc.	Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (en)	1989-05-24	1995-12-20	Merck & Co. Inc.	Purification and characterization of a glioma-derived growth factor
US5808003A (en)	1989-05-26	1998-09-15	Perimmune Holdings, Inc.	Polyaminocarboxylate chelators
WO1990015142A1 (en)	1989-06-09	1990-12-13	Gropep Pty. Ltd.	Growth hormone fusion proteins
JPH0327320A (en)	1989-06-26	1991-02-05	Ajinomoto Co Inc	Human b cell differentiation factor pharmaceutical composition
WO1991000360A1 (en)	1989-06-29	1991-01-10	Medarex, Inc.	Bispecific reagents for aids therapy
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (en) *	1989-07-26	1991-01-31	Behringwerke Ag	ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
FR2650598B1 (en)	1989-08-03	1994-06-03	Rhone Poulenc Sante	DERIVATIVES OF ALBUMIN WITH THERAPEUTIC FUNCTION
CU22222A1 (en)	1989-08-03	1995-01-31	Cigb	PROCEDURE FOR THE EXPRESSION OF HETEROLOGICAL PROTEINS PRODUCED IN A FUSION FORM IN ESCHERICHIA COLI, ITS USE, EXPRESSION VECTORS AND RECOMBINANT STRAINS
GB8927480D0 (en)	1989-12-05	1990-02-07	Delta Biotechnology Ltd	Mutant fungal strain detection and new promoter
US5073627A (en) *	1989-08-22	1991-12-17	Immunex Corporation	Fusion proteins comprising GM-CSF and IL-3
US5436146A (en)	1989-09-07	1995-07-25	The Trustees Of Princeton University	Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) *	1989-09-19	2000-05-16	Maxim Pharmaceuticals, Inc.	Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en) *	1989-09-21	2000-05-16	Rudolf Edgar Dr. Falk	Treatment of conditions and disease
IE66494B1 (en)	1989-09-26	1996-01-10	Immunex Corp	Granulocyte-colony stimulating factor receptors
JP3127158B2 (en)	1989-10-05	2001-01-22	オプテイン，インコーポレイティド	Cell-free synthesis and isolation of novel genes and polypeptides
FR2653020B1 (en)	1989-10-17	1993-03-26	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEUKEMIA.
GB8924021D0 (en)	1989-10-25	1989-12-13	Celltech Ltd	Recombinant dna method and vectors for the use therein
US5676954A (en)	1989-11-03	1997-10-14	Vanderbilt University	Method of in vivo delivery of functioning foreign genes
JP3056782B2 (en)	1989-11-03	2000-06-26	ヴァンダービルトユニバーシティ	Pharmaceutical compositions for expression of genes in target organs
US5580560A (en) *	1989-11-13	1996-12-03	Novo Nordisk A/S	Modified factor VII/VIIa
US5173408A (en)	1989-11-13	1992-12-22	Lange Louis George Iii	Mammalian pancreatic cholesterol esterase
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5116944A (en)	1989-12-29	1992-05-26	Neorx Corporation	Conjugates having improved characteristics for in vivo administration
JPH03201987A (en)	1989-12-29	1991-09-03	Tonen Corp	Human serum albumin fragment
US5780225A (en)	1990-01-12	1998-07-14	Stratagene	Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en)	1990-01-11	1991-07-25	Molecular Affinities Corporation	Production of antibodies using gene libraries
DE69120146T2 (en)	1990-01-12	1996-12-12	Cell Genesys Inc	GENERATION OF XENOGENIC ANTIBODIES
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
ATE135044T1 (en) *	1990-01-25	1996-03-15	Univ Washington	FACTOR X-LACI HYBRID PROTEIN
JPH04211375A (en)	1990-02-05	1992-08-03	Ajinomoto Co Inc	Synthetic gene and production of human serum albumin using the synthetic gene
US5747334A (en)	1990-02-15	1998-05-05	The University Of North Carolina At Chapel Hill	Random peptide library
US5208018A (en) *	1990-03-19	1993-05-04	Brigham And Women's Hospital	Treatment of cachexia with interleukin 2
FR2660863B1 (en) *	1990-04-17	1994-01-21	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF PRIMITIVE CANCERS OF THE POWDER.
US5264618A (en)	1990-04-19	1993-11-23	Vical, Inc.	Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
WO1991018088A1 (en)	1990-05-23	1991-11-28	The United States Of America, Represented By The Secretary, United States Department Of Commerce	Adeno-associated virus (aav)-based eucaryotic vectors
US5766897A (en) *	1990-06-21	1998-06-16	Incyte Pharmaceuticals, Inc.	Cysteine-pegylated proteins
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
ES2063515T3 (en)	1990-07-10	1995-01-01	Boehringer Ingelheim Int	IFN-ALPHA O-GLYCOSYLATED.
US5225341A (en)	1990-07-19	1993-07-06	The Regents Of The University Of California	Biologically safe plant transformation system using a ds transposon
US5202239A (en) *	1990-08-07	1993-04-13	Scios Nova Inc.	Expression of recombinant polypeptides with improved purification
US5071872A (en)	1990-08-14	1991-12-10	The Ohio State University Research Foundation	Method for improving interleukin-2 activity using aci-reductone compounds
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (en)	1990-08-29	1998-02-02	Genpharm Int	Production and use of transgenic, non-human animals capable of forming heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5391183A (en) *	1990-09-21	1995-02-21	Datascope Investment Corp	Device and method sealing puncture wounds
IT1242149B (en)	1990-09-27	1994-02-16	Consiglio Nazionale Ricerche	CODING NUCLEOTID SEQUENCE FOR A HUMAN PROTEIN WITH REGULATORY PROPERTIES OF ANGIOGENESIS
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DK0553244T4 (en)	1990-10-05	2005-08-01	Celldex Therapeutics Inc	Targeted immunostimulation with bispecific reagents
JPH07108232B2 (en)	1990-10-09	1995-11-22	エム・ディ・リサーチ株式会社	Method for producing peptide or protein
WO1992008802A1 (en)	1990-10-29	1992-05-29	Cetus Oncology Corporation	Bispecific antibodies, method of production, and uses thereof
US5173414A (en)	1990-10-30	1992-12-22	Applied Immune Sciences, Inc.	Production of recombinant adeno-associated virus vectors
FR2668368B1 (en)	1990-10-30	1995-03-10	Roussel Uclaf	USE OF A POLYPEPTIDE HAVING THE ACTIVITY OF HUMAN INTERLEUKIN 2 FOR PREPARING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF MALIGNANT EPITHELIAL TUMORS.
JPH0638771A (en)	1990-10-31	1994-02-15	Tonen Corp	Expression of human protein disulfide isomerase gene and production of polypeptide by co-expression with the gene
US5353535A (en)	1990-11-05	1994-10-11	Plumly George W	Floor type advertising apparatus
EP0513336B1 (en)	1990-11-29	2003-11-12	Institut National De La Recherche Agronomique (Inra)	New variants derived from interferons of type i, production process thereof and their applications
WO1992009690A2 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with altered binding properties
US5272080A (en) *	1991-02-19	1993-12-21	Pharmavene, Inc.	Production of butyrylcholinesterase
US5833982A (en)	1991-02-28	1998-11-10	Zymogenetics, Inc.	Modified factor VII
US5272070A (en)	1991-03-08	1993-12-21	Board Of Regents, The University Of Texas System	Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en)	1991-03-12	1992-09-13	Yasutaka Igari	Composition for sustained-release of erythropoietin
US5811396A (en)	1991-03-14	1998-09-22	The United States Of America As Represented By The Department Of Health And Human Services	TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (en)	1991-03-28	1999-06-23	Merck & Co. Inc.	Vascular endothelial cell growth factor C subunit
US5374617A (en)	1992-05-13	1994-12-20	Oklahoma Medical Research Foundation	Treatment of bleeding with modified tissue factor in combination with FVIIa
AU662148B2 (en)	1991-04-10	1995-08-24	Scripps Research Institute, The	Heterodimeric receptor libraries using phagemids
EP0509841A3 (en)	1991-04-18	1993-08-18	Tonen Corporation	Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en)	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
DK0511011T3 (en)	1991-04-26	1997-03-10	Surface Active Ltd	New antibodies and methods for their use
US5330901A (en)	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
US5646012A (en) *	1991-04-30	1997-07-08	Rhone-Poulenc Rorer S.A.	Yeast promoter and use thereof
FR2676070B1 (en)	1991-04-30	1994-09-30	Rhone Poulenc Rorer Sa	YEAST PROMOTER AND ITS USE.
DE69233482T2 (en)	1991-05-17	2006-01-12	Merck & Co., Inc.	Method for reducing the immunogenicity of antibody variable domains
US5304473A (en) *	1991-06-11	1994-04-19	Eli Lilly And Company	A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
WO1992022324A1 (en)	1991-06-14	1992-12-23	Xoma Corporation	Microbially-produced antibody fragments and their conjugates
FR2677996B1 (en)	1991-06-21	1993-08-27	Rhone Poulenc Rorer Sa	CLONING AND / OR EXPRESSION VECTORS PREPARATION AND USE.
US5851795A (en)	1991-06-27	1998-12-22	Bristol-Myers Squibb Company	Soluble CTLA4 molecules and uses thereof
US5844095A (en) *	1991-06-27	1998-12-01	Bristol-Myers Squibb Company	CTLA4 Ig fusion proteins
US5223408A (en) *	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
JPH05292972A (en)	1991-07-29	1993-11-09	Tonen Corp	Improved yeast expression system
US5723719A (en)	1991-08-08	1998-03-03	Health Research Inc.	Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (en)	1991-08-14	1993-02-18	Detlev Prof Dr Med Ganten	Transgenic rats that contain at least one human gene in their genome that is involved in blood pressure regulation
ES2136092T3 (en)	1991-09-23	1999-11-16	Medical Res Council	PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
NZ245015A (en) *	1991-11-05	1995-12-21	Transkaryotic Therapies Inc	Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6270989B1 (en)	1991-11-05	2001-08-07	Transkaryotic Therapies, Inc.	Protein production and delivery
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
CA2122717C (en)	1991-11-08	2003-07-15	David C. Anderson	Hemoglobins as drug delivery agents
US5786883A (en) *	1991-11-12	1998-07-28	Pilkington Barnes Hind, Inc.	Annular mask contact lenses
ES2227512T3 (en)	1991-12-02	2005-04-01	Medical Research Council	PRODUCTION OF ANTIBODIES AGAINST SELF-ANTIGENS FROM REPERTORIES OF ANTIBODY SEGMENTS FIXED IN A PHOTO.
US6348327B1 (en) *	1991-12-06	2002-02-19	Genentech, Inc.	Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5540923A (en) *	1991-12-06	1996-07-30	Landsforeningen Til Kraeftens Bekaemplse	Interferon proteins
US5428139A (en)	1991-12-10	1995-06-27	The Dow Chemical Company	Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
JPH07506720A (en)	1992-01-07	1995-07-27	アテナ　ニューロサイエンシーズ，　インコーポレイテッド	Transgenic animal model of Alzheimer's disease
GB9200417D0 (en) *	1992-01-09	1992-02-26	Bagshawe Kenneth D	Cytotoxic drug therapy
FR2686620B1 (en)	1992-01-27	1995-06-23	Rhone Poulenc Rorer Sa	HUMAN SERUM-ALBUMIN, PREPARATION AND USE.
FR2686899B1 (en) *	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686901A1 (en)	1992-01-31	1993-08-06	Rhone Poulenc Rorer Sa	NOVEL ANTITHROMBOTIC POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2686900B1 (en)	1992-01-31	1995-07-21	Rhone Poulenc Rorer Sa	NOVEL POLYPEPTIDES HAVING GRANULOCYTE COLONY STIMULATION ACTIVITY, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
PT627940E (en)	1992-03-05	2003-07-31	Univ Texas	USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZED TUMORS
US5230886A (en)	1992-03-18	1993-07-27	Trustees Of Boston University	Tumor cell suppression
DK36392D0 (en) *	1992-03-19	1992-03-19	Novo Nordisk As	USE OF CHEMICAL COMPOUND
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
US5573905A (en)	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US5460954A (en)	1992-04-01	1995-10-24	Cheil Foods & Chemicals, Inc.	Production of human proinsulin using a novel vector system
US5229109A (en)	1992-04-14	1993-07-20	Board Of Regents, The University Of Texas System	Low toxicity interleukin-2 analogues for use in immunotherapy
US5775745A (en)	1992-06-09	1998-07-07	Hoppe Holding Ag	Latch and lockset system
US5686268A (en)	1992-06-19	1997-11-11	Pfizer Inc.	Fused proteins
US5505931A (en)	1993-03-04	1996-04-09	The Dow Chemical Company	Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (en)	1992-07-08	2002-03-25	三菱ウェルファーマ株式会社	Method for producing human serum albumin
FR2694294B1 (en) *	1992-07-30	1994-09-09	Rhone Poulenc Rorer Sa	Yeast promoter and its user.
CA2337745C (en)	1992-07-31	2005-04-12	Genentech, Inc.	Human growth hormone aqueous formulation
US5602307A (en)	1992-08-12	1997-02-11	Baylor College Of Medicine	Non-human animal having predefined allele of a cellular adhesion gene
DE4226971C2 (en) *	1992-08-14	1997-01-16	Widmar Prof Dr Tanner	Modified fungal cells and processes for the production of recombinant products
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US5728553A (en)	1992-09-23	1998-03-17	Delta Biotechnology Limited	High purity albumin and method of producing
US5731490A (en)	1992-09-29	1998-03-24	The Ontario Cancer Institute	Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en) *	1992-10-14	1994-05-09	Regents Of The University Of Colorado, The	Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (en) *	1992-11-10	1995-04-14	Rhone Poulenc Rorer Sa	Antitumor compositions containing taxane derivatives.
TW402639B (en)	1992-12-03	2000-08-21	Transkaryotic Therapies Inc	Protein production and protein delivery
US5478745A (en)	1992-12-04	1995-12-26	University Of Pittsburgh	Recombinant viral vector system
US5441050A (en)	1992-12-18	1995-08-15	Neoprobe Corporation	Radiation responsive surgical instrument
US6221958B1 (en) *	1993-01-06	2001-04-24	Societe De Conseils De Recherches Et D'applications Scientifiques, Sas	Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en)	1993-01-19	1996-02-06	Amgen Inc.	Transgenic animal models for thrombocytopenia
US5593972A (en)	1993-01-26	1997-01-14	The Wistar Institute	Genetic immunization
FR2701953B1 (en)	1993-02-22	1995-05-24	Centre Nat Rech Scient	Multi-VIP fusion protein and method for preparing recombinant VIP.
US5441734A (en) *	1993-02-25	1995-08-15	Schering Corporation	Metal-interferon-alpha crystals
US5780021A (en)	1993-03-05	1998-07-14	Georgetown University	Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en)	1993-03-17	1999-02-09	University Of Washington	Methods for eliciting or enhancing reactivity to HER-2/neu protein
ES2169074T3 (en) *	1993-05-21	2002-07-01	Novo Nordisk Healthcare Ag	FACTOR VII MODIFIED TO INHIBIT THE VASCULAR RESENOSIS OR THE TANK DEPOSIT.
ATE301201T1 (en)	1993-06-07	2005-08-15	Vical Inc	PLASMIDS USABLE FOR GENE THERAPY
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
DK82893D0 (en) *	1993-07-08	1993-07-08	Novo Nordisk As	PEPTIDE
GB9317618D0 (en)	1993-08-24	1993-10-06	Royal Free Hosp School Med	Polymer modifications
US5521086A (en) *	1993-09-16	1996-05-28	Cephalon, Inc.	Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5459031A (en)	1993-11-05	1995-10-17	Amgen Inc.	Methods for controlling sialic acid derivatives in recombinant glycoproteins
WO1995015982A2 (en)	1993-12-08	1995-06-15	Genzyme Corporation	Process for generating specific antibodies
WO1995020401A1 (en)	1994-01-31	1995-08-03	Trustees Of Boston University	Polyclonal antibody libraries
US5605793A (en)	1994-02-17	1997-02-25	Affymax Technologies N.V.	Methods for in vitro recombination
US5837458A (en)	1994-02-17	1998-11-17	Maxygen, Inc.	Methods and compositions for cellular and metabolic engineering
US5834252A (en)	1995-04-18	1998-11-10	Glaxo Group Limited	End-complementary polymerase reaction
US5932780A (en)	1994-02-28	1999-08-03	Yissum Research Development Company Of Hebrew University Of Jerusalem	Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en)	1994-03-05	1994-04-20	Delta Biotechnology Ltd	Yeast strains and modified albumins
US6608182B1 (en)	1994-03-08	2003-08-19	Human Genome Sciences, Inc.	Human vascular endothelial growth factor 2
US5629286A (en) *	1994-03-31	1997-05-13	Brewitt; Barbara	Homeopathic dilutions of growth factors
US5646113A (en)	1994-04-07	1997-07-08	Genentech, Inc.	Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (en)	1994-05-06	1996-05-31	Rhone Poulenc Rorer Sa	New biologically active polypeptides, their preparation and pharmaceutical composition containing them.
GB9411356D0 (en)	1994-06-07	1994-07-27	Delta Biotechnology Ltd	Yeast strains
US5516637A (en)	1994-06-10	1996-05-14	Dade International Inc.	Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en)	1994-06-15	1999-11-16	Systemix, Inc.	Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) *	1994-06-16	1997-06-17	Novo Nordisk A/S	Synthetic leader peptide sequences
US5623054A (en)	1994-06-23	1997-04-22	The General Hospital Corporation	Crucifer AFT proteins and uses thereof
JPH0851982A (en)	1994-08-11	1996-02-27	Asahi Glass Co Ltd	Modified gene coding human serum albumen
US5574008A (en)	1994-08-30	1996-11-12	Eli Lilly And Company	Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) *	1994-09-16	2000-06-06	Bar-Ilan University	Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
KR100507431B1 (en)	1994-11-07	2005-12-21	휴먼 게놈 사이언시즈, 인코포레이티드	Tumor Necorsis Factor-γ
FR2726471B1 (en) *	1994-11-07	1997-01-31	Pf Medicament	PROCESS FOR IMPROVING THE IMMUNOGENICITY OF AN IMMUNOGENIC COMPOUND OR A HAPTENA AND APPLICATION TO THE PREPARATION OF VACCINES
FR2726576B1 (en)	1994-11-07	1997-01-31	Pf Medicament	PRODUCTION OF HYDROPHOBIC PEPTIDE-LIKE PEPTIDES, RECOMBINANT PEPTIDE, CORRESPONDING DNA SEQUENCE
AT403167B (en)	1994-11-14	1997-11-25	Immuno Ag	SELECTION AND EXPRESSION OF FOREIGN PROTEINS BY MEANS OF A SELECTION-AMPLIFICATION SYSTEM
US5695750A (en)	1994-11-25	1997-12-09	The United States Of America As Represented By The Secretary Of The Army	Compositions for use to deactivate organophosphates
DE69534265T2 (en) *	1994-12-12	2006-05-04	Beth Israel Deaconess Medical Center, Inc., Boston	CHIMERIC CYTOKINS AND ITS USE
US5652224A (en)	1995-02-24	1997-07-29	The Trustees Of The University Of Pennsylvania	Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en)	1995-03-01	1999-07-27	Ludwig Institute For Cancer Research	Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) *	1995-03-17	1998-11-17	Takeda Chemical Industries, Ltd.	Stabilized interface for iontophoresis
JP2758154B2 (en)	1995-04-06	1998-05-28	エフ・ホフマン−ラロシユアーゲー	Liquid preparations containing interferon
AU5632296A (en)	1995-04-27	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
JPH11507205A (en)	1995-04-27	1999-06-29	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	Human tumor necrosis factor receptor
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5480640A (en)	1995-05-02	1996-01-02	Schering Corporation	Alpha interferon for treating prostate cancer
MX9708537A (en)	1995-05-05	1998-02-28	Human Genome Sciences Inc	Human chemokine beta-8, chemokine beta-1 and macrophage inflammatory protein-4.
US5728915A (en)	1995-05-08	1998-03-17	Children's Hospital, Inc.	Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en)	1995-05-18	1998-01-06	National Jewish Center For Immunology & Respiratory Medicine	Gene therapy for T cell regulation
US6001625A (en)	1995-05-19	1999-12-14	The United States Of America As Represented By The Secretary Of The Army	Site-directed mutagenesis of esterases
US6387365B1 (en)	1995-05-19	2002-05-14	Schering Corporation	Combination therapy for chronic hepatitis C infection
US5741815A (en) *	1995-06-02	1998-04-21	Lai; Ching-San	Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en)	1995-06-07	1998-09-08	Alliance Pharmaceutical Corp.	Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) *	1995-07-21	1998-03-17	Constantia Gruppe	Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en)	1995-07-25	1998-09-22	The Regents Of The University Of California	Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5766620A (en) *	1995-10-23	1998-06-16	Theratech, Inc.	Buccal delivery of glucagon-like insulinotropic peptides
CA2329474C (en)	1995-11-02	2002-02-26	Schering Corporation	Continuous low-dose cytokine infusion therapy
US6048964A (en) *	1995-12-12	2000-04-11	Stryker Corporation	Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
GB9526733D0 (en) *	1995-12-30	1996-02-28	Delta Biotechnology Ltd	Fusion proteins
US6110707A (en) *	1996-01-19	2000-08-29	Board Of Regents, The University Of Texas System	Recombinant expression of proteins from secretory cell lines
US6087129A (en) *	1996-01-19	2000-07-11	Betagene, Inc.	Recombinant expression of proteins from secretory cell lines
US6150337A (en)	1996-01-23	2000-11-21	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
US5767097A (en) *	1996-01-23	1998-06-16	Icn Pharmaceuticals, Inc.	Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
JP2978435B2 (en)	1996-01-24	1999-11-15	チッソ株式会社	Method for producing acryloxypropyl silane
DE19639601A1 (en)	1996-02-28	1997-09-04	Bayer Ag	Parapox viruses that contain foreign DNA, their production and their use in vaccines
US6045788A (en) *	1996-02-28	2000-04-04	Cornell Research Foundation, Inc.	Method of stimulation of immune response with low doses of IL-2
US5912229A (en) *	1996-03-01	1999-06-15	Novo Nordisk Als	Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (en) *	1996-03-04	2006-07-12	第一アスビオファーマ株式会社	Method for culturing microorganisms with methanol metabolism
WO1997033904A1 (en)	1996-03-12	1997-09-18	Human Genome Sciences, Inc.	Death domain containing receptors
AU728146B2 (en)	1996-03-14	2001-01-04	Immune Response Corporation, The	Targeted delivery of genes encoding interferon
AU5711196A (en)	1996-03-14	1997-10-01	Human Genome Sciences, Inc.	Apoptosis inducing molecule i
WO1997034997A1 (en) *	1996-03-21	1997-09-25	Human Genome Sciences, Inc.	Human endometrial specific steroid-binding factor i, ii and iii
WO1997034911A1 (en)	1996-03-22	1997-09-25	Human Genome Sciences, Inc.	Apoptosis inducing molecule ii
US6204022B1 (en) *	1996-04-12	2001-03-20	Pepgen Corporation And University Of Florida	Low-toxicity human interferon-alpha analogs
WO1997039775A1 (en) *	1996-04-23	1997-10-30	Chugai Seiyaku Kabushiki Kaisha	Cerebral stroke/cerebral edema preventive or remedy containing il-8 binding inhibitor as active ingredient
JP4172726B2 (en) *	1996-05-22	2008-10-29	ルイトポルド・ファーマシューティカルズ・インコーポレーテッド	Formulation containing a covalent complex of cis-docosahexaenoic acid and docetaxel
US6300065B1 (en) *	1996-05-31	2001-10-09	Board Of Trustees Of The University Of Illinois	Yeast cell surface display of proteins and uses thereof
DE59711957D1 (en) *	1996-06-11	2004-10-28	Roche Diagnostics Gmbh	RECOMBINANT BLOOD CLOTHING PROTEASES
ATE294863T1 (en)	1996-07-15	2005-05-15	Chugai Pharmaceutical Co Ltd	NOVEL VEGF-LIKE FACTORS
JP4440344B2 (en)	1996-08-16	2010-03-24	シェーリングコーポレイション	Mammalian cell surface antigens; related reagents
AU731123B2 (en)	1996-08-16	2001-03-22	Human Genome Sciences, Inc.	Human endokine alpha
DK1749836T3 (en)	1996-08-23	2009-08-31	Vegenics Ltd	Recombinant vascular endothelial cell growth factor D
AU7364696A (en) *	1996-09-18	1998-04-14	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like genes
US6225290B1 (en)	1996-09-19	2001-05-01	The Regents Of The University Of California	Systemic gene therapy by intestinal cell transformation
US5994112A (en)	1996-10-09	1999-11-30	Incyte Pharmaceuticals, Inc.	Human protein tyrosine kinase
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
US5955508A (en) *	1996-10-15	1999-09-21	Loyola University Of Chicago	Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
AU4988697A (en)	1996-10-24	1998-05-15	Vion Pharmaceuticals, Inc.	Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
JP2001503263A (en)	1996-10-25	2001-03-13	ヒューマンジノームサイエンシーズ，インコーポレイテッド	Neutrokine α
JPH10134761A (en)	1996-10-30	1998-05-22	Ebara Corp	Ion implantation device and method
US5908830A (en) *	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
UA65549C2 (en) *	1996-11-05	2004-04-15	Елі Ліллі Енд Компані	Use of glucagon-like peptides such as glp-1, glp-1 analog, or glp-1 derivative in methods and compositions for reducing body weight
GB9623205D0 (en) *	1996-11-07	1997-01-08	Eurand Int	Novel pharmaceutical compositions
ATE387495T1 (en)	1996-12-03	2008-03-15	Amgen Fremont Inc	FULLY HUMANE ANTIBODIES THAT BIND EGFR
US5833994A (en)	1997-01-08	1998-11-10	Paracelsian, Inc.	Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
DE69834027D1 (en)	1997-01-14	2006-05-18	Human Genome Sciences Inc	TUMOR NECROSIS FACTOR RECEPTOR 5
JP2001527387A (en) *	1997-01-24	2001-12-25	ノボノルディスクアクティーゼルスカブ	Synthetic leader peptide sequence
ES2284199T5 (en)	1997-01-28	2011-11-14	Human Genome Sciences, Inc.	RECEIVER 4 CONTAINING DEATH DOMAIN (DR4: DEATH RECEIVER 4), MEMBER OF THE TNF RECEPTORS SUPERFAMILY AND TRAIL UNION (APO-2L).
EP0921817B1 (en)	1997-01-29	2001-03-28	PolyMASC Pharmaceuticals plc	Pegylation process
GB2324529A (en)	1997-02-21	1998-10-28	Merck & Co Inc	A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
US7026447B2 (en) *	1997-10-09	2006-04-11	Human Genome Sciences, Inc.	53 human secreted proteins
US6030961A (en) *	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
US7227002B1 (en)	1997-04-14	2007-06-05	Micromet Ag	Human antibodies that bind human 17-A1/EpCAM tumor antigen
TW577759B (en) *	1997-04-18	2004-03-01	Ipsen Pharma Biotech	Sustained release compositions in the form of microcapsules or implants and the process for their preparation
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6140368A (en)	1997-05-05	2000-10-31	The Regents Of The University Of California	Naphthols useful in antiviral methods
WO1998054202A1 (en)	1997-05-30	1998-12-03	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor tr10
US6071743A (en)	1997-06-02	2000-06-06	Subsidiary No. 3, Inc.	Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
JP2002503963A (en)	1997-06-11	2002-02-05	ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド	Human tumor necrosis factor receptor TR9
GB9713412D0 (en)	1997-06-26	1997-08-27	Delta Biotechnology Ltd	Improved protein expression strains
US5858719A (en)	1997-07-17	1999-01-12	Incyte Pharmaceuticals, Inc.	Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ES2162393T3 (en)	1997-09-21	2001-12-16	Schering Corp	COMBINATION THERAPY TO ERADICATE DETECTABLE HCV-RNA IN PATIENTS WITH CHRONIC HEPATITIS C INFECTION.
US6172046B1 (en) *	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6201072B1 (en) *	1997-10-03	2001-03-13	Macromed, Inc.	Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
EP1042342A4 (en) *	1997-10-09	2003-04-09	Human Genome Sciences Inc	53 human secreted proteins
CN1174993C (en)	1997-11-03	2004-11-10	人体基因组科学有限公司	VEGI, an inhibitor of angiogenesis and tumor growth
WO1999029314A1 (en) *	1997-12-08	1999-06-17	Bristol-Myers Squibb Company	Novel salts of metformin and method
AU763719B2 (en) *	1997-12-08	2003-07-31	Merck Patent Gmbh	Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6017545A (en) *	1998-02-10	2000-01-25	Modi; Pankaj	Mixed micellar delivery system and method of preparation
US6221378B1 (en) *	1998-02-10	2001-04-24	Generex Pharmaceuticals Incorporated	Mixed micellar delivery system and method of preparation
DE19813802A1 (en)	1998-03-27	1999-11-11	Retro Tech Gmbh	Anti-viral effects of propolis through inhibition of viral nucleic acid polymerases
GB9806631D0 (en)	1998-03-28	1998-05-27	Safeglass Europ Limited	Safetyglass
US6251868B1 (en)	1998-04-30	2001-06-26	Teijin Limited	Method for treating a human immunodeficiency virus infection
PT956861E (en)	1998-05-15	2002-08-30	Schering Corp	COMBINED THERAPY UNDERSTANDING RIBAVIRIN AND ALPHA INTERFERENCE IN PATIENTS WITHOUT PREVIOUS ANTIVIRAL TREATMENT HAVING CHRONIC INFECTION BY HEPATITIS C VIRUS
CN1119352C (en)	1998-05-15	2003-08-27	中国科学院上海生物化学研究所	Express and purification of human serum albumin in pichia
US5970300A (en) *	1998-06-01	1999-10-19	Xerox Corporation	Apparatus for applying scents to paper in a printer/copier
WO1999066054A2 (en) *	1998-06-15	1999-12-23	Genzyme Transgenics Corp.	Erythropoietin analog-human serum albumin fusion protein
CN1105727C (en)	1998-06-17	2003-04-16	上海海济医药生物工程有限公司	Process for preparing recombined human serum albumin
WO1999066936A1 (en)	1998-06-24	1999-12-29	Emory University	Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
GB9817084D0 (en)	1998-08-06	1998-10-07	Wood Christopher B	A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
US6346543B1 (en) *	1998-08-17	2002-02-12	Aventis Pharma S.A.	Use of a taxoid to treat abnormal cell proliferation in the brain
US6193997B1 (en) *	1998-09-27	2001-02-27	Generex Pharmaceuticals Inc.	Proteinic drug delivery system using membrane mimetics
US6048891A (en) *	1998-12-17	2000-04-11	Loma Linda University Medical Center	Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US20030009013A1 (en) *	1998-12-30	2003-01-09	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
GB9902000D0 (en)	1999-01-30	1999-03-17	Delta Biotechnology Ltd	Process
US6348192B1 (en) *	1999-05-11	2002-02-19	Bayer Corporation	Interleukin-2 mutein expressed from mammalian cells
US6514500B1 (en) *	1999-10-15	2003-02-04	Conjuchem, Inc.	Long lasting synthetic glucagon like peptide {GLP-!}
BR0010725A (en)	1999-05-19	2002-02-19	Lexigen Pharm Corp	Expression and export of interferon-alpha proteins as fc fusion proteins
PE20010288A1 (en) *	1999-07-02	2001-03-07	Hoffmann La Roche	ERYTHROPOYETIN DERIVATIVES
US20020048571A1 (en) *	1999-07-19	2002-04-25	Jeno Gyuris	Chimeric polypeptides of serum albumin and uses related thereto
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
CA2388432A1 (en)	1999-10-21	2001-04-26	Monsanto Company	Post-translational modification of recombinant proteins produced in plants
US6569832B1 (en) *	1999-11-12	2003-05-27	Novo Nordisk A/S	Inhibition of beta cell degeneration
US20050100991A1 (en) *	2001-04-12	2005-05-12	Human Genome Sciences, Inc.	Albumin fusion proteins
EP2298355A3 (en) *	2000-04-12	2011-06-29	Human Genome Sciences, Inc.	Albumin fusion proteins
US6946134B1 (en)	2000-04-12	2005-09-20	Human Genome Sciences, Inc.	Albumin fusion proteins
ES2237574T5 (en) *	2000-05-15	2017-08-09	F. Hoffmann-La Roche Ag	Liquid pharmaceutical composition containing an erythropoietin derivative
US7101561B2 (en) *	2000-12-01	2006-09-05	Innogenetics N.V.	Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
HU230603B1 (en)	2000-12-07	2017-03-28	Eli Lilly And Company	Glp-1 fusion proteins
US7070973B2 (en)	2000-12-26	2006-07-04	Board Of Regents Of The University Of Nebraska	Butyrylcholinesterase variants and methods of use
US20050244931A1 (en) *	2001-04-12	2005-11-03	Human Genome Sciences, Inc.	Albumin fusion proteins
US20050054051A1 (en) *	2001-04-12	2005-03-10	Human Genome Sciences, Inc.	Albumin fusion proteins
US20060084794A1 (en) *	2001-04-12	2006-04-20	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002310122A1 (en)	2001-05-25	2002-12-09	Human Genome Sciences, Inc.	Chemokine beta-1 fusion proteins
JP2004537580A (en)	2001-08-10	2004-12-16	エピックスメディカル，インコーポレイテッド	Polypeptide conjugates with extended circulating half-life
AU2002332041A1 (en)	2001-10-05	2003-04-22	Human Genome Sciences, Inc.	Albumin fusion proteins
DK1578771T3 (en) *	2001-10-10	2013-06-10	Novo Nordisk As	Remodeling and glycoconjugation of peptides
US20080194481A1 (en)	2001-12-21	2008-08-14	Human Genome Sciences, Inc.	Albumin Fusion Proteins
KR101271635B1 (en) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	Albumin fusion proteins
US20080167238A1 (en)	2001-12-21	2008-07-10	Human Genome Sciences, Inc.	Albumin Fusion Proteins
PT1463751E (en) *	2001-12-21	2013-08-26	Human Genome Sciences Inc	Albumin fusion proteins
AU2002364587A1 (en)	2001-12-21	2003-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003054182A2 (en)	2001-12-21	2003-07-03	Nexia Biotechnologies, Inc.	Production of butyrylcholinesterases in transgenic mammals
MXPA04012496A (en) *	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Pegylated factor vii glycoforms.
CN1241946C (en) *	2002-07-01	2006-02-15	美国福源集团	Human serum albumins recombined merge protein having hyperplasia stimulation function to multiple cells
US6913890B2 (en) *	2002-12-18	2005-07-05	Palo Alto Research Center Incorporated	Process for preparing albumin protein conjugated oligonucleotide probes
CA2513213C (en)	2003-01-22	2013-07-30	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2004216476B2 (en) *	2003-02-27	2009-01-08	Takeda Pharmaceutical Company Limited	Method for the validatable inactivation of pathogens in a biological fluid by irradiation
DK1729795T3 (en)	2004-02-09	2016-04-11	Human Genome Sciences Inc	Albumin fusion proteins
US20060051859A1 (en) *	2004-09-09	2006-03-09	Yan Fu	Long acting human interferon analogs
US7436410B2 (en) *	2005-04-01	2008-10-14	Seiko Epson Corporation	System and method for programming a controller
WO2007021494A2 (en)	2005-08-12	2007-02-22	Human Genome Sciences, Inc.	Albumin fusion proteins
US7438904B1 (en)	2005-10-04	2008-10-21	University Of Kentucky Research Foundation	High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
US8008257B2 (en)	2005-10-20	2011-08-30	University Of Ottawa Heart Institute	ANF fusion proteins
EP1816201A1 (en) *	2006-02-06	2007-08-08	CSL Behring GmbH	Modified coagulation factor VIIa with extended half-life
US8334365B2 (en)	2006-06-07	2012-12-18	Human Genome Sciences, Inc.	Albumin fusion proteins
DK2717898T3 (en) *	2011-06-10	2019-03-25	Bioverativ Therapeutics Inc	COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF

2001
- 2001-04-12 EP EP10075375A patent/EP2298355A3/en not_active Withdrawn
- 2001-04-12 EP EP10075387A patent/EP2267026A1/en not_active Withdrawn
- 2001-04-12 EP EP01932549A patent/EP1274720A4/en not_active Ceased
- 2001-04-12 US US09/833,041 patent/US6994857B2/en not_active Expired - Lifetime
- 2001-04-12 JP JP2001577463A patent/JP2003530852A/en active Pending
- 2001-04-12 JP JP2001576855A patent/JP2003530838A/en active Pending
- 2001-04-12 EP EP01932546A patent/EP1274719A4/en not_active Ceased
- 2001-04-12 AU AU2001259066A patent/AU2001259066A1/en not_active Abandoned
- 2001-04-12 EP EP01934875A patent/EP1278767A4/en not_active Withdrawn
- 2001-04-12 EP EP10075010.8A patent/EP2236152B1/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/012009 patent/WO2001079271A1/en not_active Application Discontinuation
- 2001-04-12 AU AU2001264563A patent/AU2001264563A1/en not_active Abandoned
- 2001-04-12 US US09/832,929 patent/US6926898B2/en not_active Expired - Lifetime
- 2001-04-12 CA CA002405563A patent/CA2405563A1/en not_active Abandoned
- 2001-04-12 ES ES10075010.8T patent/ES2484966T3/en not_active Expired - Lifetime
- 2001-04-12 EP EP08075327A patent/EP1983055A1/en not_active Withdrawn
- 2001-04-12 EP EP10075499A patent/EP2357008A1/en not_active Withdrawn
- 2001-04-12 JP JP2001577427A patent/JP2003530846A/en active Pending
- 2001-04-12 AU AU2001274809A patent/AU2001274809A1/en not_active Abandoned
- 2001-04-12 JP JP2001576866A patent/JP2003530839A/en active Pending
- 2001-04-12 EP EP06076852A patent/EP1832599A3/en not_active Ceased
- 2001-04-12 JP JP2001577426A patent/JP2003531590A/en active Pending
- 2001-04-12 US US09/833,118 patent/US6905688B2/en not_active Expired - Lifetime
- 2001-04-12 WO PCT/US2001/011988 patent/WO2001077137A1/en not_active Application Discontinuation
- 2001-04-12 AU AU2001266557A patent/AU2001266557A1/en not_active Abandoned
- 2001-04-12 EP EP01944114A patent/EP1276756A4/en not_active Withdrawn
- 2001-04-12 US US09/833,117 patent/US20030171267A1/en not_active Abandoned
- 2001-04-12 EP EP10075388A patent/EP2311872A1/en not_active Withdrawn
- 2001-04-12 CA CA002405701A patent/CA2405701A1/en not_active Withdrawn
- 2001-04-12 EP EP10075064A patent/EP2206720A1/en not_active Withdrawn
- 2001-04-12 JP JP2001575607A patent/JP2004506407A/en active Pending
- 2001-04-12 WO PCT/US2001/011850 patent/WO2001079442A2/en not_active Application Discontinuation
- 2001-04-12 JP JP2001577428A patent/JP2003530847A/en active Pending
- 2001-04-12 AU AU2001259063A patent/AU2001259063A1/en not_active Abandoned
- 2001-04-12 CA CA2747325A patent/CA2747325A1/en not_active Abandoned
- 2001-04-12 WO PCT/US2001/012013 patent/WO2001079444A2/en active Application Filing
- 2001-04-12 ES ES10075011.6T patent/ES2529300T3/en not_active Expired - Lifetime
- 2001-04-12 CA CA2405557A patent/CA2405557C/en not_active Expired - Lifetime
- 2001-04-12 EP EP01941457A patent/EP1278544A4/en not_active Ceased
- 2001-04-12 EP EP08075909A patent/EP2067488A1/en not_active Withdrawn
- 2001-04-12 CA CA002405550A patent/CA2405550A1/en not_active Abandoned
- 2001-04-12 EP EP10075391A patent/EP2295456A1/en not_active Ceased
- 2001-04-12 DK DK10075010.8T patent/DK2236152T3/en active
- 2001-04-12 US US09/833,245 patent/US20040010134A1/en not_active Abandoned
- 2001-04-12 US US09/832,501 patent/US20030199043A1/en not_active Abandoned
- 2001-04-12 CA CA002405525A patent/CA2405525A1/en not_active Abandoned
- 2001-04-12 EP EP01938994A patent/EP1276849A4/en not_active Withdrawn
- 2001-04-12 CA CA002405912A patent/CA2405912A1/en not_active Abandoned
- 2001-04-12 CA CA002405709A patent/CA2405709A1/en not_active Abandoned
- 2001-04-12 EP EP10075164A patent/EP2213743A1/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/011991 patent/WO2001079480A1/en not_active Application Discontinuation
- 2001-04-12 DK DK10075011.6T patent/DK2216409T3/en active
- 2001-04-12 WO PCT/US2001/011924 patent/WO2001079443A2/en active Application Filing
- 2001-04-12 EP EP10075316A patent/EP2275557A1/en not_active Withdrawn
- 2001-04-12 AU AU2001262942A patent/AU2001262942A1/en not_active Abandoned
- 2001-04-12 EP EP06015131A patent/EP1803730A1/en not_active Withdrawn
- 2001-04-12 EP EP01937179A patent/EP1276856A4/en not_active Withdrawn
- 2001-04-12 WO PCT/US2001/012008 patent/WO2001079258A1/en active Application Filing
- 2001-04-12 EP EP10075011.6A patent/EP2216409B1/en not_active Expired - Lifetime
- 2001-04-12 AU AU2001261024A patent/AU2001261024A1/en not_active Abandoned
2005
- 2005-03-14 US US11/078,663 patent/US7507414B2/en not_active Expired - Lifetime
- 2005-03-14 US US11/078,914 patent/US7482013B2/en not_active Expired - Lifetime
2007
- 2007-10-29 US US11/927,593 patent/US20080261877A1/en not_active Abandoned
- 2007-10-29 US US11/927,600 patent/US9821039B2/en not_active Expired - Fee Related
- 2007-10-29 US US11/927,602 patent/US10080785B2/en not_active Expired - Lifetime
- 2007-10-29 US US11/927,555 patent/US20090285816A9/en not_active Abandoned
- 2007-10-29 US US11/927,607 patent/US20080269126A1/en not_active Abandoned
- 2007-10-29 US US11/927,610 patent/US20080269127A1/en not_active Abandoned
- 2007-10-29 US US11/927,617 patent/US20080269128A1/en not_active Abandoned
- 2007-10-29 US US11/927,583 patent/US20120141415A1/en not_active Abandoned
- 2007-10-30 US US11/929,677 patent/US7785599B2/en not_active Expired - Fee Related
2009
- 2009-02-04 US US12/365,878 patent/US20110280830A9/en not_active Abandoned
2011
- 2011-05-16 JP JP2011109620A patent/JP2011217750A/en active Pending
- 2011-08-18 US US13/212,879 patent/US20120252732A1/en not_active Abandoned
2012
- 2012-05-04 US US13/464,248 patent/US8946156B2/en not_active Expired - Fee Related
2013
- 2013-04-02 US US13/855,434 patent/US9775888B2/en not_active Expired - Lifetime
- 2013-04-02 US US13/855,454 patent/US9849162B2/en not_active Expired - Fee Related
- 2013-10-17 JP JP2013216509A patent/JP2014057589A/en active Pending
2016
- 2016-11-04 BE BE2016C059C patent/BE2016C059I2/nl unknown
- 2016-11-04 FR FR16C0043C patent/FR16C0043I2/en active Active
2017
- 2017-12-21 US US15/850,371 patent/US20180200346A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20040171123A1 (en)	2004-09-02
WO2001079258A9 (en)	2002-02-28
EP2267026A1 (en)	2010-12-29
CA2405550A1 (en)	2001-10-25
DK2216409T3 (en)	2015-01-05
WO2001079271A9 (en)	2002-02-28
CA2405557A1 (en)	2001-10-25
US7785599B2 (en)	2010-08-31
JP2003531590A (en)	2003-10-28
JP2014057589A (en)	2014-04-03
US7507414B2 (en)	2009-03-24
EP1278767A4 (en)	2003-11-12
WO2001079271A1 (en)	2001-10-25
US6994857B2 (en)	2006-02-07
JP2003530847A (en)	2003-10-21
EP1276849A2 (en)	2003-01-22
EP2216409B1 (en)	2014-12-03
EP1276756A1 (en)	2003-01-22
US20140010798A1 (en)	2014-01-09
EP2311872A1 (en)	2011-04-20
EP1274719A2 (en)	2003-01-15
EP1278544A4 (en)	2004-08-18
EP1832599A2 (en)	2007-09-12
US20030125247A1 (en)	2003-07-03
EP2357008A1 (en)	2011-08-17
US20110280830A9 (en)	2011-11-17
WO2001079480A1 (en)	2001-10-25
EP2067488A1 (en)	2009-06-10
EP2298355A2 (en)	2011-03-23
EP1803730A1 (en)	2007-07-04
FR16C0043I1 (en)	2016-12-09
US9775888B2 (en)	2017-10-03
ES2529300T3 (en)	2015-02-18
ES2484966T3 (en)	2014-08-12
CA2405563A1 (en)	2001-10-25
EP1278767A1 (en)	2003-01-29
EP2298355A3 (en)	2011-06-29
US9849162B2 (en)	2017-12-26
EP2275557A1 (en)	2011-01-19
US20080269125A1 (en)	2008-10-30
JP2003530846A (en)	2003-10-21
US8946156B2 (en)	2015-02-03
US20030219875A1 (en)	2003-11-27
EP1276849A4 (en)	2004-06-09
WO2001079258A1 (en)	2001-10-25
WO2001079444A3 (en)	2002-05-23
WO2001079442A2 (en)	2001-10-25
JP2011217750A (en)	2011-11-04
FR16C0043I2 (en)	2020-04-10
WO2001079480A9 (en)	2003-09-18
EP1276756A4 (en)	2004-06-09
EP1278544A2 (en)	2003-01-29
DK2236152T3 (en)	2014-07-07
CA2405701A1 (en)	2001-10-25
EP2236152B1 (en)	2014-06-04
CA2405709A1 (en)	2001-10-25
CA2405525A1 (en)	2001-10-25
EP1274720A1 (en)	2003-01-15
US20050266532A1 (en)	2005-12-01
US20080269126A1 (en)	2008-10-30
US9821039B2 (en)	2017-11-21
EP1276856A4 (en)	2004-06-09
EP2216409A1 (en)	2010-08-11
JP2003530839A (en)	2003-10-21
JP2004506407A (en)	2004-03-04
WO2001079443A3 (en)	2002-02-21
AU2001274809A1 (en)	2001-10-30
US20120252732A1 (en)	2012-10-04
WO2001077137A9 (en)	2002-05-02
WO2001079442A3 (en)	2002-06-06
WO2001079444A2 (en)	2001-10-25
US20090285816A9 (en)	2009-11-19
EP2213743A1 (en)	2010-08-04
US20080269127A1 (en)	2008-10-30
US20080269128A1 (en)	2008-10-30
US6926898B2 (en)	2005-08-09
CA2747325A1 (en)	2001-10-25
AU2001262942A1 (en)	2001-10-30
JP2003530852A (en)	2003-10-21
EP2295456A1 (en)	2011-03-16
US20080131399A1 (en)	2008-06-05
US10080785B2 (en)	2018-09-25
US20080267962A1 (en)	2008-10-30
US20050266533A1 (en)	2005-12-01
US20140004095A1 (en)	2014-01-02
US6905688B2 (en)	2005-06-14
US20070287173A9 (en)	2007-12-13
US20080261877A1 (en)	2008-10-23
US20040010134A1 (en)	2004-01-15
EP1832599A3 (en)	2007-11-21
BE2016C059I2 (en)	2020-08-20
AU2001259066A1 (en)	2001-10-30
JP2003530838A (en)	2003-10-21
AU2001261024A1 (en)	2001-10-30
EP1276856A1 (en)	2003-01-22
US20030171267A1 (en)	2003-09-11
EP1274720A4 (en)	2004-08-18
US20120141415A1 (en)	2012-06-07
AU2001266557A1 (en)	2001-10-23
AU2001259063A1 (en)	2001-10-30
US20100189686A1 (en)	2010-07-29
US20180200346A1 (en)	2018-07-19
US20130266553A1 (en)	2013-10-10
US20030199043A1 (en)	2003-10-23
EP2206720A1 (en)	2010-07-14
WO2001077137A1 (en)	2001-10-18
EP1274719A4 (en)	2004-05-19
US7482013B2 (en)	2009-01-27
WO2001079443A2 (en)	2001-10-25
US20120141449A1 (en)	2012-06-07
EP1983055A1 (en)	2008-10-22
EP2236152A1 (en)	2010-10-06
CA2405912A1 (en)	2001-10-18
CA2405557C (en)	2013-09-24

Publication	Publication Date	Title
AU2001261024A1 (en)	2001-10-30	Albumin fusion proteins
AU2002364586A1 (en)	2003-07-30	Albumin fusion proteins
AU2002364587A1 (en)	2003-07-30	Albumin fusion proteins
AU2002332041A1 (en)	2003-04-22	Albumin fusion proteins
AU2001291049A1 (en)	2002-03-26	Defensin-antigen fusion proteins
AU2002307255A1 (en)	2002-10-28	Vegf fusion proteins
HUP0302529A3 (en)	2009-03-30	Glp-1 fusion proteins
AU6058500A (en)	2001-01-31	Fusion protein and uses thereof
AU3562299A (en)	1999-11-23	Inhibin-hbc fusion protein
AU5553600A (en)	2001-01-31	Fusion proteins incorporating lysozyme
GB9913437D0 (en)	1999-08-11	Fusion proteins
AU9798398A (en)	1999-05-03	Gfp-annexin fusion proteins
IL148550A0 (en)	2002-09-12	Transgenically produced fusion proteins
AU2001291050A1 (en)	2002-03-26	Viral chemokine-tumur antigen fusion proteins
AU2002232707A1 (en)	2002-05-06	Transmembrane proteins
AU2002229675A1 (en)	2002-07-08	Selective cytotoxic fusion proteins
AU2002239747A1 (en)	2002-06-03	Cystoskeleton-associated proteins
AU2001244863A1 (en)	2001-10-08	Apoptin-associating protein
AU2002224379A1 (en)	2002-04-22	Clasp-2 transmembrane proteins
AU2001261423A1 (en)	2001-11-20	Vasodilator-thrombolytic fusion proteins and conjugates
AU2001231918A1 (en)	2001-08-07	Scscntfr/nnt-1 fusion protein
AU2001241044A1 (en)	2001-09-17	Mitf-associated proteins
SI1463751T1 (en)	2013-11-29	Albumin fusion proteins
AU2755801A (en)	2001-07-16	Pp14 fusion proteins and methods for making and using the same
AU2001278777A1 (en)	2002-03-04	Irap-binding protein